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1. Introduction 
1.1. Type 1 Diabetes 
About 1 of 11 adults suffer from diabetes mellitus, a disease that has become the ninth major 
cause of death worldwide [1]. Diabetes mellitus is a chronic disease that is caused by a lack of 
or resistance to insulin. Insulin is a hormone produced by pancreatic  cells, which regulates 
blood glucose metabolism by promoting uptake of glucose into cells. Normal fasting blood 
glucose levels are less than 100 mg/dL (5.6 mmol/L) and vital for normal function of tissues 
[2]. A continuous elevation of blood glucose levels can lead to toxicity and chronic damage to 
tissues such as nerves and vessels. To monitor three-month plasma glucose concentrations 
and glucose control in patients, glycated hemoglobin (HbA1C) has been established as a 
valuable diagnostic marker, as it is a form of hemoglobin that gets glycated proportionately 
based on blood glucose levels. 90% of all diabetes cases are attributable to Type 2 Diabetes 
(T2D), a chronic metabolic disease based on increased insulin resistance of the cells. Type 1 
Diabetes (T1D), however, is a form of diabetes mellitus which is thought to be caused by an 
autoimmune-mediated destruction of  cells of the endocrine pancreas, culminating in a 
complete insulin deficiency and compromised glucose homeostasis. The vast majority of T1D 
cases is of autoimmune nature, while only a small minority of T1D cases are idiopathic with a 
distinct lack of autoimmunity [3]. Predominantly, T1D is a chronic disease of children and 
adolescents, but recent studies have shown that autoimmune diabetes can vary in age at 
onset and span across all age groups [4]. Core characteristics of T1D are the triad of polyuria, 
polydipsia and polyphagia, as well as hyperglycemia and the need for exogenous insulin 
substitution. Although the discoveries of insulin and other modern therapies have improved 
long term survival of patients with T1D greatly, the effects of macrovascular and microvascular 
complications can be detrimental for the patient.  As prevalence and incidence rates rise, the 
burden of both T1D and T2D on patients and the health care system increases drastically. 
Currently, the estimated cost of T1D treatment accounts for 10% of the total health care costs 
in countries such as the UK [5]. Additionally, it was shown that the generic health-related 
quality of life in young children with T1D was significantly lowered compared to children 
without T1D of the same age [6]. Large epidemiological studies have shown that improved 
blood glucose control over the last decades has significantly lowered the risk of complications 
and cardiovascular disease in patients with T1D. However, the age adjusted relative risk of 
cardiovascular disease in children with T1D is still ten times greater than that of the general 
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population [7]. Despite great efforts and investments of today’s society, many questions about 
epidemiology, pathogenesis and the effectiveness of current therapies and possible cures for 
T1D remain unanswered. 
 
1.1.1. Epidemiology of Type 1 Diabetes 
T1D is one of the most common autoimmune diseases in children and adolescents. There are 
two peaks of age at onset, the first at 5-7 years of age and the second during puberty. T1D 
accounts for approximately 5-10% of all diabetes cases around the world [1]. Its incidence rate 
varies greatly globally, with more than 60 cases per 100 000 people per year in Finland and 
less than 0.1 cases per 100 000 people per year in China. T1D accounts for more than 85% of 
all diabetes mellitus cases in youth under the age of 20 years. Data from large epidemiological 
studies such as DIAMOND and EURODIAB have shown that annual incidence rates of T1D are 
continuously increasing by 2-5% [8]. Such drastic rises in incidence cannot solely be attributed 
to genetic predisposition, but rather to a combination of genetic susceptibility and 
environmental influences. 
 
1.1.2. Pathophysiology of Type 1 Diabetes 
T1D is a heterogeneous disorder with variations in pathogenic processes, genetics and 
phenotypes. The majority of cases are autoimmune mediated, with patients showing either 
autoantibodies in their serum or genetic variations in genes that control immune functions. A 
small collective of T1D patients lack all signs of autoimmunity, with no clear understanding of 
pathogenesis. Recently, it has become more and more complicated to differentiate and 
diagnose T1D correctly, because prevalence of T2D in children has risen as obesity of the 
young is drastically increasing worldwide [9]. Generally, T1D is a result of autoimmune 
mediated destruction of pancreatic  cells and a lack of insulin secretion. Current hypotheses 
suggest a combination of genetic susceptibility and immunological and environmental factors 
as the cause for T1D. 
 
T1D is a polygenic disease with almost 40 different gene loci identified to be involved in 
pathogenesis. There are a few genes with very large effect and many genes with smaller 
effects on risk of disease. Most prominently, the human leukocyte antigen (HLA) region on 
chromosome 6 makes up almost half of all genetic susceptibility for T1D. Both, HLA class I and 
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HLA class II alleles are significantly linked to T1D, with some alleles playing a predisposing 
(DRB1*03-DQB1*0201 [DR3]; DRB1*04-DQB1*0302 [DR4]) and others playing a protective 
(DQB1*0602) role [10, 11]. Notably, most gene loci associated with increased risk of T1D are 
involved in the immune response. Due to the autoimmune aspect of T1D, lymphatic tissues 
are thought to be heavily involved in pathogenesis.   
 
In the thymus, presentation of antigen and central tolerance play crucial roles in maintaining 
immunological homeostasis. Naturally, overtly self-reactive immune cells are negatively 
selected (central tolerance). Self-reactive T cells that escape these mechanisms are usually 
suppressed in the periphery (peripheral tolerance). Dysfunction of these regulatory 
mechanisms may result in autoimmune disorder. For example, the autoimmune regulator 
protein AIRE is a transcription factor mainly expressed in the thymus, which regulates the 
expression of autoantigens and is linked to immune tolerance. It has been shown that patients 
with mutations of AIRE suffer from an autoimmune syndrome known as APECED or APS1, 
which is also associated with T1D [10]. In total, genome-wide association studies (GWAS) have 
identified 55 non-HLA gene loci to at least partially confer susceptibility, including INS, 
PTPN22, CTLA-4 and amongst others a lectin-like gene called CLEC16A. 
 
Despite the clear link between genetic susceptibility and risk of disease, the concordance rate 
in monozygotic twins is 30-50% [10], suggesting an influence of environmental factors. A 
plethora of such potential environmental factors have been investigated extensively, including 
nutrients, viruses, toxins and the microbiome. Epidemiological studies have linked viral 
infections, especially infections with enteroviruses such as coxsackie virus B4 (CV-B4), to T1D 
and autoimmunity. In some patients, CV-B4 was isolated from pancreatic tissue of patients 
with T1D, indicating a possible relation between disease and virus. Current hypotheses 
suggest an important role of CV-B4 in pathogenesis of T1D through activation of the innate 
immune system and autoimmunity by molecular mimicry [12, 13]. Additionally, the effect of 
diets and nutrition on disease development has been critically reviewed. Early exposure to 
cow’s milk in an infant’s diet may increase risk of autoimmunity and T1D [14]. This hypothesis 
was supported by a study that showed a reduction of T1D markers such as autoantibodies in 
children with genetic susceptibility after supplementing breast milk with ultra-hydrolyzed milk 
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formula [15]. Other factors such as vitamin D deficiency or reduced intake of omega-3 fatty 
acids may also be implicated in T1D pathogenesis. 
 
In recent years, the gut microbiota has become a popular topic of research in the field of T1D 
pathogenesis. As modern day medicine shows greatly improved control of infectious disease 
in the western world, the incidence of autoimmune disorders is on the rise [16]. Most recently, 
it was found that patients with T1D show significant differences in their gut microbiota 
compositions compared to healthy controls [17]. If these changes in composition are caused 
by environmental factors such as diet and hygiene, and whether these changes are cause or 
result of T1D, needs to further be investigated.   
 
The pathology and natural history of T1D have been extensively studied using pancreatic 
biopsies and entire organs of people with serological evidence of recent-onset of disease. 
Analyses of these tissues showed that more than 70% of pancreatic islets show a complete 
lack of insulin. About 20% of pancreatic islets still contain insulin but already display signs of 
inflammation (insulitis), and a small percentage of pancreatic islets show no sign of pathology 
[18]. Typically, pancreata of T1D patients show decreased weight, atrophy in the dorsal region, 
a lobular loss of  cells and heterogenous lobular insulitis. Histologically, pancreatic islets show 
a loss of  cells, which increases with the duration of disease and leads to reduced levels of 
insulin in the remaining  cells over time. Eventually, the remaining pancreatic islets are 
completely insulin-deficient, but show a preservation of all other hormone secreting cells, 
which suggests a selective loss of  cells in the pancreas. Immunostaining of pancreatic tissue 
of recent-onset patients shows infiltration of CD8+ cytotoxic T cells as the most prevalent cell 
population in insulitis lesions, followed by CD68+ macrophages, CD4+ T cells and CD20+ B cells. 
In contrast, FoxP3+ T regulatory cells (Treg) and natural killer cells (NK) are almost absent from 
insulitis lesions. Interestingly, once  cells are insulin-deficient, all subsets of immune cells are 
significantly reduced in islets. This indicates that there is some intrinsic stimulus during 
insulitis that promotes immune response and attracts immune cells [19]. 
 
Additionally, another typical feature of T1D compared with T2D is the presence of 
autoantibodies in the serum of patients. As a sign of autoimmunity, autoantibodies can be 
found in 70-80% of T1D patients at onset of disease [14]. The most common autoantibodies 
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in T1D are those against insulin (IAA), glutamic acid decarboxylase (GAD65), tyrosine 
phosphatase 2 (IA-2) and zinc transporter (ZnT8) [20]. Despite expansive information on the 
prevalent autoantibodies in T1D, it is still unclear whether these antibodies are cause or result 
of autoimmunity in the pancreas. So far, autoantibodies have mostly been of predictive or 
diagnostic value. In some large studies such as the Diabetes Prevention Trial (DPT-1) the 5 year 
risk of T1D was 25% for subjects with one antibody, 50% for subjects with two antibodies and 
more than 70% for subjects with three or more antibodies in their serum [21].  Although most 
theories disregard autoantibodies as pathogenic, some studies found an improvement in T1D 
patients after treatment with Rituximab, a B cell depleting drug, suggesting a potential role of 
autoantibodies in pathogenesis of T1D [22]. 
 
 
Figure 1  Pathogenesis of Type 1 Diabetes, with permission, as published by van Belle et al. [23] 
 
Today, most theories agree that T1D is caused by a final pathway of cellular autoimmunity in 
which autoantigen-specific T cells destroy insulin producing  cells in the pancreas. Once 
autoreactive T cells are activated through antigen presentation by local antigen presenting 
cells (APCs), they differentiate into effector cells. To initiate and convey insulitis and T1D, both 
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CD4+ and CD8+ T cells are required. CD4+ T cells are helper cells mainly required for activation 
and stimulation of CD8+ T cells and B cells. There are multiple subsets of CD4+ T cells. Th1 cells 
exacerbate T1D by cell mediated immunity and the expression of pro-inflammatory 
chemokines such as IFN and IL-2. Th2 cells protect from T1D by humoral immunity and the 
production the immunoregulatory chemokines IL-4 and IL-10. Th17 cells are pro-inflammatory 
T cells also involved in the pathogenesis of T1D, whereas Tregs are understood to serve as 
immunoregulatory and immunosuppressive cells [24]. CD4+ T cells require the major 
histocompatibility class (MHC) II molecules for activation. On the other hand, CD8+ T cells 
recognize antigen presented through the MHC class I pathway. Pancreatic  cells only express 
MHC class I molecules and no MHC class II molecules [25]. Studies have shown that non-obese 
diabetic (NOD) mice, which lacked MHC class I molecules, were protected from insulitis and 
T1D, which indicates that CD8+ T cells are essential for T1D initiation [26]. Once activated, CD8+ 
T cells proliferate into cytotoxic T cells. Cytotoxic CD8+ cells can interact with pancreatic  cells 
directly through a cell-to-cell contact, or indirectly by releasing pro-inflammatory cytokines 
and perforin, which leads to the destruction of pancreatic  cells [24]. 
 
Over the past decade, FoxP3+ Tregs were implicated in the pathogenesis of T1D. Tregs were 
found to suppress activation, proliferation and expansion of CD4+ and CD8+ T cells and 
therefore help to maintain peripheral tolerance [27]. Patients with T1D show a quantitative 
and qualitative deficit in Tregs, which could mean reduction in peripheral tolerance and an 
increase in immune response [14]. 
 
In summary, individuals with predisposing genetic susceptibility can develop T1D if triggered 
by concurrent environmental effects. CD8+ T cells specific for pancreatic antigens attack 
pancreatic  cells, which die and release pancreatic antigen. These antigens are processed and 
presented by APCs, which stimulates and activates CD4+ T cells and B cells. B cells differentiate 
into plasma cells and start producing autoantibodies. Meanwhile, environmental factors 
shape the inflammatory setting and suppress Tregs, and further enable pro-inflammatory 
immune cells. With the increasing cellular stress and destruction of pancreatic  cells, the 
production and secretion of insulin ceases and blood glucose levels rise.  
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1.1.3. Management of Type 1 Diabetes 
In 1921, insulin was discovered as a breakthrough therapy for T1D. Since then, substitution of 
exogenous insulin has become the standard treatment of T1D patients. Despite the many 
advantages of insulin replacement therapy, persistent metabolic homeostasis cannot always 
be maintained, which in turn can lead to common micro- or macrovascular damage and 
complications such as retinopathy or cardiovascular disease. Therefore, a more rigorous blood 
glucose management is required. Today, modern treatment of T1D usually includes the use of 
insulin analogues and mechanical devices such as pumps and blood sugar monitors. There are 
different viable options for treatment of T1D. With multiple injections of insulin per day, the 
patient uses a long-acting basal insulin and a rapid-acting bolus insulin. In recent years, the 
use of continuous subcutaneous insulin injections (CSII) has become more popular, with 
studies showing a lower HbA1C compared to multiple injections a day. Additionally, recent 
studies have shown that real-time blood glucose monitoring decreases time spent in 
hypoglycaemia and lowers HbA1C. In combination, real-time blood glucose monitoring and CSII 
are now being used as sensor-augmented pump therapy. In the future, sensor-augmented 
pump therapy may be enhanced even further by algorithms which simulate a closed-loop 
system similar to an artificial pancreas [28, 29]. 
 
1.2. The immune system 
Humans are constantly exposed to potentially damaging influences from the environment. As 
a host defense, the immune system has evolved to protect the human body from such harm. 
Its main task is to detect and eliminate infectious agents, known as pathogens, as well as 
keeping the body’s own defective cells in check. Pathogenic microorganisms can differ greatly 
in their mechanisms of pathogenesis. Hence, the immune system comprises a variety of 
systems and processes, all of which interact with each other to protect from infection and 
disease. Without an immune system, the body would be left vulnerable to pathogens such as 
microbes, toxins and allergens. There are two major parts of the immune system, the innate 
and the adaptive system. 
 
1.2.1. Innate immune system 
The innate immune system is an immediate, yet unspecific response and can be considered a 
first line of defense. It exists in almost all living organisms. As a first layer of defense, physical 
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barriers such as the epithelium with tight cell-cell contacts, or the protective mucus barrier in 
the respiratory tract, stop pathogens from entering the body. Once these barriers are 
breached, the immediate innate response includes antimicrobial proteins such as defensins, 
which can bind to the cell membrane of a microbe and disrupt its stability. If a pathogen 
bypasses the initial defense, it encounters another layer of the innate immune system, the so-
called complement system. This system is comprised of soluble proteins in blood and bodily 
fluids that can be activated directly by contact with pathogens or indirectly by contact with 
antibodies bound to pathogens. Once activated, a biochemical chain of reactions aids (or 
complements) the immune system in detecting, tagging and eliminating pathogens. Cells of 
the innate immune system can be divided into two groups. On the one hand, phagocytes (i.e. 
macrophages, neutrophils, dendritic cells) consume opsonized pathogens, destroying the 
threat and activating other parts of the immune system by releasing inflammatory mediators 
such as chemokines. On the other hand, natural killer cells are capable of inducing apoptosis 
directly in infected cells [30-33]. 
 
1.2.2. Adaptive immune system 
Unlike the innate immune response, the adaptive immune system is highly specific to its target 
antigens and provides an immunological memory for re-infections. There are two major cell 
types involved in adaptive response: T lymphocytes (T cells) and B lymphocytes (B cells). All 
lymphocytes derive from the bone marrow, yet only B cells mature there. Naïve B cells 
differentiate into either plasma cells, which produce antibodies, or B memory cells. Precursor 
T cells migrate to the thymus, a site where complex selection and maturation takes place. At 
the end of development, T cells express either CD8 or CD4 as a surface protein. CD8+ T cells 
leave the thymus as cytotoxic T cells, whereas CD4+ T cells can develop into at least five 
different subsets of effector cells called Th1, Th2, Th17, Tregs and follicular helper cells (TFH). After 
maturation, lymphocytes migrate into the bloodstream and spread to secondary lymphoid 
tissues, ready to encounter antigen. 
 
A functioning immune system must be able to recognize millions of different pathogens at any 
time. In contrast to cells of the innate immune system, which express pattern recognition 
receptors that recognize features common to many pathogens, cells of the adaptive immune 
system each carry one receptor specific to a single antigen. Once an antigen-specific 
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lymphocyte gets activated, it proliferates into a clone of identical cells, all expressing the same 
antigen receptor. The highly diverse repertoire of antigen-specific receptor molecules in 
humans is encoded by genes, which are generated through somatic rearrangement of a few 
hundred gene elements during maturation in the bone marrow and thymus. 
 
Although the B cell receptor (BCR) and T cell receptor (TCR) are evolutionarily quite similar, 
the way B cells and T cells recognize antigen is fundamentally different. B cells directly bind 
antigen with their BCR. In contrast, T cells only recognize antigens that have been processed 
and presented as peptides on the surface of APCs. Specifically, T cells will only recognize 
peptides if they are bound to a particular group of surface proteins encoded in a cluster of 
genes called the major histocompatibility complex or human leukocyte antigen complex. MHC 
molecules are assembled inside the cell and transported to the cell surface where they display 
a single processed peptide to T cells. There are two major classes: MHC class I and MHC class 
II. MHC class I molecules can be found on most human cells and present peptides derived from 
intracellular proteins, such a degraded viral protein. Peptide bound to MHC class I molecules 
can interact with CD8+ cytotoxic T cells, which in turn activate and kill infected cells. In 
contrast, MHC class II molecules are mostly present on the surface of APCs (dendritic cells, 
macrophages) and display peptides previously internalized through phagocytosis or 
endocytosis. Peptide bound to MHC class II molecules activates CD4+ T cells. These will release 
chemokines and other effector molecules to effect target cells directly or promote activation 
of other immune cells. Thus, T cells play a crucial role in both cell-mediated and humoral 
immune response [30-33]. 
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1.2.3. The immune response 
 
 
Figure 2  Overview of the primary immune response 
The innate system is the first line of defense against infectious agents. Its components are of different nature: 
physical barriers (e.g. epithelium), immune cells (macrophages) and other molecules such as the complement 
system play a crucial role in innate immunity. The adaptive system can be divided into two systems, the 
humoral and cellular response. B cells differentiate into plasma cells and generate antigen specific antibodies. 
Antibodies can tag foreign agents and help eliminate pathogens. Some B cells differentiate into memory cells, 
which will reactivate quickly during a secondary response. T cells differentiate into a plethora of different 
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subpopulations, most prominently CD4+ T helper cells and CD8+ cytotoxic T cells. CD4+ T helper cells stimulate 
other immune cells and mediate immune response, while CD8+ cytotoxic T cells directly help eliminate 
pathogens. T cells can also differentiate into memory T cells for secondary responses. 
 
1.3. Autoimmune disease 
Autoimmune diseases such as T1D, Multiple Sclerosis (MS), Systemic Lupus Erythematosus 
(SLE), Crohn’s Disease, Celiac Disease and others are considered a leading cause of death and 
disability worldwide, with a recently estimated prevalence of 7.6 - 9.4% in the general 
population [34]. Over the past decades, incidence rates for autoimmune diseases such as T1D 
have risen significantly [35], severely effecting both patient quality of life and health care 
systems [36], and making them a prime target for modern day research.  
Multiple studies have shown an increased risk of autoimmune disease in monozygotic twins 
[37] and first-degree relatives of affected individuals [38], implying a genetic component in 
susceptibility for autoimmune disease. Additionally, environmental factors such as nutrition, 
tobacco smoking, infectious disease or the microbiota are known to be of critical importance 
in autoimmune disease [39, 40]. Today, autoimmune disease can be seen as a complex 
disorder that requires genetic predisposition and environmental factors to trigger 
autoimmunity and tissue damage. Yet, despite significant advances in our understanding of 
human autoimmunity, many questions considering etiology and pathogenesis of autoimmune 
disease remain unanswered. 
 
1.3.1. Autoimmunity 
The human immune system uses both innate and adaptive mechanisms to protect the body 
against a plethora of pathogenic organisms, as well as toxins and allergens. Its main goal is to 
detect foreign pathogenic antigens and to launch a powerful immune response to eliminate 
any threat. At the same time, excessive damage to self-tissue must be avoided. Critical to a 
functioning immune system is the ability to distinguish between self and non-self. Lack of self-
discrimination leads to an uncoordinated immune response against self and results in 
autoimmunity. Autoimmunity can lead to chronic inflammation, tissue damage and 
autoimmune disease. 
 
Generally, through a process of central tolerance, T cell differentiation in the thymus 
generates such a repertoire of T cells that induces strong immune response against foreign 
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antigen but maintains relatively weak responsiveness to self-peptide. This process starts with 
the maturation of progenitor thymocytes in the thymus. 
 
1.3.2. T cell development 
During T cell maturation in the thymus, thymocytes go through a series of developmental 
stages which can be characterized by the expression of certain cell surface proteins, most 
prominently the TCR complex (CD3 and the TCR chains) and the co-receptor proteins CD4 and 
CD8. The first cells migrating to the thymus do not bear any of these characteristic surface 
proteins. At this point, the precursor cells can give rise to two populations of T cells: a majority 
: T cell line and a minority : T cell line. After contact with stromal cells in the thymus, the 
progenitor cells commit to the T cell lineage but still lack the surface molecules CD4 and CD8. 
These so-called double negative (DN) T cells undergo another series of developmental stages 
ranging from DN1 to DN4, which are characterized by the up and down regulation of surface 
molecules such as CD25 and CD44 and gene rearrangement within the TCR -chain locus. 
Eventually, DN4 cells start to express CD4 and CD8 and turn into double positive (DP) CD4+ 
CD8+ thymocytes. DP thymocytes express low levels of : TCRs with ranging affinities for 
antigen. At this point, the affinity of TCR to the self-peptide:MHC complex determines the fate 
of the thymocyte [33]. 
 
1.3.3. Positive and negative selection in the thymus 
DP thymocytes are programmed to die by neglect, unless they are rescued by TCR signaling 
after binding self-peptide:MHC complex – a process called positive selection. Most DP 
thymocytes express TCRs with no affinity to self-peptide:MHC and die. Only about 1 - 5% of 
DP thymocytes express : TCRs with low affinity to self-peptide:MHC and survive. After 
positive selection, thymocytes express high levels of TCR and down regulate one of the two 
surface molecules, either CD4 or CD8, and mature into single positive (SP) CD4+ or CD8+ T cells. 
In contrast, other thymocytes express TCRs with high affinity to self-peptide:MHC complex 
and bind self-antigen too strongly. As a potential threat to self-tissue, thymocytes with high 
affinity TCRs to self-peptide are subject to negative selection, a process that eliminates highly 
reactive T cells [33, 41]. 
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In order to understand the process of T cell maturation, it is important to discuss the 
anatomical and functional compartments of the thymus. There are two major regions in the 
thymus: an outer cortex containing mostly DP and DN thymocytes and a central medulla 
harboring mostly SP thymocytes. Although most of the thymus comprises progenitor 
thymocytes, there are a number of stromal cells such as macrophages, dendritic cells (DCs) 
and epithelial cells. Positive selection of : TCR thymocytes takes place in the cortex and is 
highly dependent on a particular class of APCs known as cortical thymic epithelial cells (cTECs). 
Previously, it was thought that cTECs were important for positive selection due to an 
abundance in expression of MHC molecules and close proximity to developing thymocytes. 
Recently, however, it was shown that antigen processing in cTECs may play a vital role in 
positive selection [42]. MHC class I antigen presentation in cTECs involves a distinct 
proteasome subunit called β5t. Mice lacking β5t in the thymus were shown to have a severely 
reduced pool of positively selected CD8+ T cells [43]. Additionally, MHC class II antigen 
presentation in cTECs involves uniquely expressed proteases such as the thymus-specific 
serine protease (TSSP) and cathepsin L. Mice deficient of TSSP or cathepsin L showed a 
significantly impaired selection and immune response of CD4+ T cells [44, 45]. Furthermore, it 
was shown that MHC class II antigen presentation in cTECs is highly dependent on 
macroautophagy, a process where intracellular components are degraded and recycled [46, 
47]. 
 
While the cortex plays an important role in early T cell development and positive selection, 
the thymic medulla is involved in tolerance induction and the deletion of hyperreactive : 
TCR thymocytes. Medullary thymic epithelial cells (mTECs) are critical to tolerance induction, 
as they are capable of promiscuous gene expression of tissue-restricted antigens (TRAs) [48]. 
mTECs can present endogenously expressed self-antigen directly to T cells through MHC class 
II loading and induce negative selection of both CD4+ and CD8+ T cells [49, 50]. There are at 
least two ways how mTECs can load self-antigen onto MHC class II molecules. First, contents 
of the endoplasmic reticulum (ER) can leak into the MHC class II loading pathway. Second, just 
as in cTECs, antigen presentation of endogenous self-peptide in mTECs has been reported to 
heavily depend on macroautophagy [47]. Athymic mice which had received thymic transplants 
deficient in macroautophagy showed severe immune-mediated tissue damage, indicating a 
crucial role of autophagy in TECs, T cell selection, tolerance and autoimmunity [46]. 
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Figure 3  T cell selection in the thymus 
Naïve thymocytes enter the thymus through vessels in the subcapsular cortical region, where they encounter a 
network of cortical epithelial cells (cTEC). At first, T cell precursors are double negative (DN) and express neither 
CD4 nor CD8. As the thymocytes progress through the four DN stages, -chain rearrangement takes place. Once 
-chain rearrangement is completed, thymocytes will proliferate and express CD4 and CD8 and become double 
positive (DP). DP thymocytes move deeper into the thymic cortex, where they are presented with antigen via 
MHC molecules on cTECs. Cells that bind with self-peptide:MHC survive (positive selection), while most other 
cells die by neglect. Cells that survive positive selection migrate towards the medulla, where they are presented 
with tissue-restricted antigens (TRAs) by medullary thymic epithelial cells (mTECs) and interact with other 
antigen presenting cells (APCs). Cells that bind too strongly to self-peptide receive an apoptotic signal and die. 
The remaining cells exit the thymus as effector T cells [51-53]. 
 
1.4. Autophagy 
Autophagy is a protein degradation process essential to maintaining cellular homeostasis. It is 
a constitutive process that is also highly inducible through stress such as starvation. 
Evolutionary, it is well conserved from yeast to mammals [54]. Autophagy is required to rid 
cells of abundant protein, aggregates, organelles and nutrients. It serves as a recycling and 
fuelling mechanism within the cell. Recent studies show its involvement in tumor suppression, 
immunity, adaption to starvation or other stressors [55]. Since the discovery of autophagy-
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related genes (ATGs) in yeast, there is a greater mechanistical understanding of autophagy 
[56]. Recently, polymorphisms of autophagy related genes have been linked to disease such 
as neurodegenerative or autoimmune disease. There are three types of autophagy: 
microautophagy (as seen in yeast), chaperone-mediated autophagy (CMA) and 
macroautophagy (from here on called ‘autophagy’). 
 
1.4.1. Macroautophagy 
Autophagy has long been thought to be a non-selective process. Recent studies, however, 
suggest there are also highly specific degradation processes mediated by autophagy [57]. First, 
an isolation membrane (also called phagophore) encloses intracellular material to form a 
double-membrane vesicle, called the autophagosome. Next, autophagosomes fuse with 
lysosomes to form an autophagolysosome. Finally, enzymes contained within the 
autophagolysosome degrade the previously engulfed cytoplasmic material (see Figure 4). 
Currently, at least 41 ATGs have been identified. ATG proteins are critical in regulating 
initiation, maturation, fusion and degradation. A core ATG protein is ATG5, which is 
indispensable in autophagosome formation. A knockdown (KD) or knockout (KO) of ATG5 can 
result in downregulation or complete inhibition of autophagy. Hence, ATG5 is a commonly 
used marker for autophagy. 
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Figure 4  Overview of autophagy 
Pre-existing organelles such as the Golgi body (or endoplasmic reticulum, mitochondria) supply lipids and 
membrane vesicles to support the formation of an isolation membrane, also called phagophore. The 
phagophore encloses organelles and cytoplasm to form a vesicle called autophagosome, a process which is 
highly dependent on ATGs, e.g. ATG5. Also, the Clec16a ortholog ema in Drosophila has been shown to be 
crucial for autophagosome formation and maturation. The outer membrane of the autophagosome 
subsequently fuses with a lysosome to form an autophagolysosome. The engulfed organelles are degraded by 
lysosomal enzymes into peptides. These peptides can be re-purposed within the cell or presented as antigens 
[58, 59]. 
 
1.4.2. Autophagy in autoimmunity 
Lymphocytes are crucial to adaptive immunity. One way to activate lymphocytes is through 
antigen presentation via MHC class I and MHC class II molecules (see Chapter 1.2.2.). For 
regular activation of lymphocytes, MHC molecules are loaded with peptides previously 
processed by protein degradation systems such as the ubiquitin-proteasome or autophagy. 
Studies have demonstrated that autophagy can promote antigen presentation through MHC 
class I and MHC class II molecules and affects activation of T cells [60, 61].  Additionally, it was 
reported that autophagy deficiency in thymic epithelial cells impairs MHC class II antigen 
presentation and therefore shapes the selection of autoreactive T cells [46]. 
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1.4.3. Autophagy in thymic epithelial cells 
In contrast to most other cells, TECs show a high rate of constitutive autophagy. Additionally, 
they are the only non-hematopoietic cells which express MHC class II molecules constitutively. 
It was demonstrated that presentation of self-antigen through MCH class II molecules on TECs 
is essential for the selection of a functional T cell repertoire [46]. Regular APCs mainly display 
extracellular peptides on MHC class II molecules previously processed through endocytosis. 
TECs, however, are highly inefficient in processing and presenting extracellular peptides 
through the MHC class II pathway [46]. This suggests that TECs use other systems to load MHC 
class II molecules, systems such as autophagy. The protein H2-DM is involved in antigen 
presentation on APCs, mostly through the MHC class II pathway. In further studies, autophagy 
markers in TECs colocalized with H2-DM+ lysosomal compartments, suggesting a possible 
intersection of the autophagy pathway with the MHC class II loading process [62]. Additionally, 
it was found that genetic interference with autophagy strictly in TECs led to an altered T cell 
repertoire and severe multi-organ inflammation in mice. Remarkably, in that study, impaired 
autophagy led to altered MHC ligands on cTECs and altered TRAs in mTECs, underlining a 
possible effect of autophagy on T cell selection [46]. Despite these findings, it remains unclear 
how exactly impaired autophagy leads to an altered T cell repertoire and autoimmunity. 
 
1.4.4. Monitoring autophagy 
To this day, monitoring autophagy remains complicated. With a recent surge of interest in the 
field, especially since Yoshinori Ohsumi received the Nobel Prize in Physiology or Medicine for 
his work on autophagy in 2016, an increasing number of assays and techniques have been 
developed to investigate the process. There are two major ways of monitoring autophagy: 
direct observation of autophagy-related structures in the cell and quantification of turnover 
of autophagy related proteins. Considering that autophagy is a highly complex and dynamic 
process, it is important to measure autophagic activity. This comprises the formation of 
autophagosomes, but also the entire flow of autophagic structures, including transportation 
and release of autophagic substrates. Currently, the most common way to monitor autophagic 
flux is to quantify the levels of certain proteins, most prominently LC3 and p62 [59, 63]. 
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1.4.4.1. The microtubule-associated protein 1 light chain 3 – LC3 
As the homolog of Atg8, the microtubule-associated protein 1 light chain 3 (MAP1LC3B) 
encodes for one of the most commonly used markers for autophagy called LC3 [64]. In 
mammals, there are three known isoforms of LC3, in particular LC3A, LC3B and LC3C. The 
isoform LC3B (from here on called LC3) has been studied intensively and has been found to 
play a crucial role in the formation of autophagosomes [65]. There are two forms of the 
ubiquitin-like protein LC3. First, proLC3 is cleaved by the ATG4 protease to become LC3-I with 
a glycine residue. Then, in a ubiquitination-like process, LC3-I gets modified by ATG7, ATG3 
and the ATG16L complex with phosphatidylethanolamine to become LC3-II [65, 66]. While 
LC3-I is a soluble fraction in the cytoplasm, LC3-II is bound to most autophagic membranes, 
including the phagophore and the autophagosome. Specifically, LC3-II localizes with both the 
outer and the inner membrane of the autophagosome. Once the autophagosome fuses with 
a lysosome, the LC3-II bound to the outer membrane of the autophagosome gets cleaved by 
ATG4 protease and converted back to LC3-I [64, 66]. The LC3-II on the inner part of the 
autophagosome gets degraded by lysosomal proteases as part of autophagy. 
 
The amount of LC3-II is closely tied to the formation of autophagosomes and usually a good 
indicator of autophagy. One way to investigate autophagy is to study LC3-positive structures 
using an anti-LC3 antibody and immunofluorescence [63, 66]. Under nourished conditions, 
there are only few LC3-positive structures. In contrast, under starved conditions, there is a 
significant increase in LC3-positive structures, indicating an induction of autophagy. Although 
LC3-positive structures can signal an increase in autophagy and the formation of 
autophagosomes, they can also be a result of impaired autophagy and an accumulation of 
autophagosomes due to reduced degradation of vesicles. 
 
A more commonly used approach of studying autophagy is protein detection via the Western 
blot technique [63, 64, 66]. LC3-I and LC3-II can be separated due to different mobility in SDS-
PAGE. LC3-I can usually be detected at 16kD and LC3-II at roughly 14kD [64]. Although 
immunoblotting is a widely used method, there are pitfalls to this technique, and it can be 
difficult to interpret results. For example, LC3-I and LC3-II show different immunoreactivity 
with LC3-II binding more strongly to antibodies than LC3-I. Furthermore, after starvation, the 
amount of LC3-I decreases and the amount of LC3-II increases, as more autophagosomes are 
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formed and more LC3-I is converted to LC3-II. Levels of LC3-II, however, are dynamic and 
cannot be used for studies, as the outer-membrane LC3-II is converted back to LC3-I and the 
inner-membrane LC3-II is further degraded by autophagy. Hence, in order to measure 
autophagic turnover, lysosomal inhibitors such as pepstatin A or E64d are used to arrest 
autophagy and stop lysosomal degradation of LC3-II [64, 66]. Degradation of LC3-II is mostly 
inhibited while LC3-I remains unaffected by protease inhibitors. With this approach, it is 
possible to measure autophagic flux in the form of an LC3-II/LC3-I ratio. Normally, after 
treatment with protease inhibitors, starved wild type cells show a high LC3-II/LC3-I ratio, as 
autophagy is induced, and LC3-II accumulates due to inhibition of further degradation. In 
contrast, when autophagy is genetically impaired (Atg5 knockout), cells show a significantly 
lower LC3-II/LC3-I ratio [66]. In summary, analysis of autophagy assays can be difficult, but 
generally, if there is an increase in LC3-II after treatment with protease inhibitors, there is 
functional autophagic flux. 
 
1.4.4.2. The autophagosome cargo protein p62 
An alternative way to study autophagy is to measure levels of p62, a protein encoded by 
SQSTM1. p62 is a multifunctional protein with an LC3-interacting region (LIR) and a C-terminal 
ubiquitin-associated domain (UBA), playing an important role in autophagy as well as the 
proteasomal degradation of proteins [67]. p62 serves as a receptor for selective autophagy 
[68]. It can bind LC3 and deliver polyubiquitinated cargo proteins to autophagosomes, serving 
as a substrate of autophagy [64, 67]. It has been established that autophagy reduces levels of 
p62, while the inhibition of autophagy increases levels of p62 [69]. Although levels of p62 are 
highly dependent on autophagy, they can also be altered by transcriptional regulation and 
inhibition of proteasomal degradation. Therefore, results of p62 studies are usually 
interpreted and presented in combination with other methods, such as LC3-II turnover 
studies. 
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Figure 5  The autophagy markers LC3 and p62 
LC3 plays a major role in autophagosome formation. LC3-I is the soluble cytosolic form, while LC3-II is bound to 
most autophagic membranes, especially the inner and outer membrane of the autophagosome. LC3-II on the 
outer membrane gets cleaved by ATG4 and converted back to LC3-I. The inner membrane fraction of LC3-II gets 
degraded during autophagy [64, 70, 71]. p62 is a direct substrate of autophagy, that can recruit cargo proteins 
to the autophagosome, and is degraded by the autophagic process [67, 69]. 
 
1.5. The C-type lectin domain family 16 member A - CLEC16A 
Recent genome-wide association studies have identified CLEC16A as a new risk allele for T1D. 
CLEC16A (also KIAA0350) is a gene located within the chromosome 16p13 region and encodes 
for a C-type lectin domain family 16 member A protein. CLEC16A variation has been associated 
with a variety of autoimmune diseases. Two single nucleotide polymorphisms (SNPs) in 
particular, rs12708716 and rs2903692, are located on introns of CLEC16A and are most 
significantly linked with T1D [72, 73]. Furthermore, CLEC16A variants have been found to 
confer susceptibility for other autoimmune diseases such as MS, SLE, celiac disease, Crohn’s 
disease, primary biliary cirrhosis, alopecia areata, juvenile idiopathic arthritis, rheumatoid 
arthritis and primary adrenal insufficiency [74-81]. Despite this clear link to autoimmunity the 
function of CLEC16A is still unknown. 
 
Introduction 
 21 
1.5.1. Characteristics of CLEC16A 
The full-length gene CLEC16A encodes a protein of 1053 amino acids (aa) and consists of 24 
exons. There are thirteen transcript variants and at least three isoforms, two long and one 
short isoform [82, 83]. CLEC16A is markedly expressed in a variety of different immune cells, 
as well as other tissues such as brain, testes, thymus and intestine [84]. CLEC16A is part of the 
C-type lectin family. Proteins of this family typically express a C-type lectin-like domain (CTLD), 
which mediates Ca2+-dependent carbohydrate binding and subsequently facilitates pathogen 
recognition processes within the immune system [85]. After binding a ligand, CTLDs induce 
signal pathways through an immunoreceptor tyrosine-base activation motif (ITAM). ITAMs are 
highly conserved and can be found in most leukocytes associating with most 
immunoreceptors such as the TCR [86]. Due to its short length (only 23 aa), the CTLD of 
CLEC16A is most likely not capable of folding into a fully functional carbohydrate recognition 
domain. CTLDs, however, have been shown to have evolved and also bind other ligands such 
as lipids and (glycol-)proteins. Today, it is unclear whether the CTLD of CLEC16A is capable of 
interaction with ligands. However, further studies have revealed a potential ITAM in CLEC16A 
(aa 483-499), implicating the gene in immunoregulation. Additionally, CLEC16A contains a 
highly conserved, uncharacterized domain called FPL (aa 51-199) and a potential 
transmembrane region (TM) at amino acids 308-330 [84]. 
 
 
Figure 6  CLEC16A isoforms, based on Berge et al. [82, 84] 
Schematic visualization of the three known isoforms of CLEC16A including their respective domains (FPL, TM, 
ITAM, CTLD): Q2KHT3-1 – 3.  
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1.5.2. The 16p13 gene locus 
GWAS have found more than 40 new chromosomal regions that confer a low to moderate risk 
of T1D [87]. One of these regions is the chromosome 16p13.13 locus, which harbors CLEC16A 
and its neighboring genes CIITA, SOCS1 and DEXI [72]. The MHC class II transactivator (CIITA) 
regulates gene expression of HLA class II molecules [88] and SOCS1 is a suppressor of cytokine 
signaling, which regulates immune cell homeostasis and inflammation [89]. Additionally, DEXI 
has been identified as a novelty immunoregulatory gene which is upregulated by stimulation 
with dexamethasone, an anti-inflammatory and immunosuppressive drug [90]. Despite the 
identification of the 16p13.13 locus as a chromosomal region linked to autoimmunity, the 
specific mechanisms of susceptibility remain unknown. Recently, chromosome confirmation 
capture could show physical proximity and interaction between intron 19 of CLEC16A 
(including SNPs associated with T1D) and the promoter region of DEXI [90]. Furthermore, it 
was reported that DEXI serves as an enhancer for CIITA expression [73]. Additionally, it was 
reported that there is significant correlation between the expression of CLEC16A and SOCS1 
and DEXI in the thymus [91]. As the causal variants are associated with CLEC16A, these findings 
suggest that genetic variation in CLEC16A could regulate expression of itself and its 
neighboring genes and modulate risk of T1D. 
 
 
Figure 7  Neighboring genes on chromosome 16p13 
Schematic visualization of the 16p13 genetic locus including CLEC16A and its neighboring genes CIITA, DEXI and 
SOCS1. Based on the Human Genome Resources database at NCBI [92]. 
 
1.5.3. CLEC16A in autophagy 
CLEC16A is the human ortholog of the Drosophila gene ema (endosomal maturation 
defective). It has been reported that Ema is an endosomal membrane protein required for 
endosomal maturation [93]. In ema mutants, endosomal maturation fails to progress, and late 
endosomes and lysosomes are unable to fuse [93]. Moreover, ema was found to modulate 
size and function of autophagosomes in Drosophila fat cells [58]. Under starved conditions, 
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Ema localizes to the Golgi complex and is then recruited to the autophagosome, together with 
the Golgi protein Lva (lava lamp) [58]. Although fusion of autophagosomes with lysosomes 
was generally functional in ema mutants, there was a significant reduction in the size of 
autophagosomes [58]. Strikingly, the human ortholog CLEC16A could rescue autophagy in ema 
mutants, implicating the autoimmunity-associated gene CLEC16A in autophagy [58, 93]. 
 
1.6. Gene knockdown models 
An increasing number of genes have been associated with autoimmune disease, yet very little 
is known about their function or specific effect on susceptibility. Studying the knockdown of 
these genes is a valuable tool to better understand the link between susceptibility genes and 
their individual contribution to disease pathogenesis. 
 
RNA interference (RNAi) is a well conserved, sequence-specific and post-transcriptional gene 
silencing mechanism of cells used to defend against pathogenic nucleic acids. RNAi takes place 
when a small RNA strand pairs with a complementary messenger RNA (mRNA) strand. There 
are two kinds of RNA which can facilitate RNAi: microRNA (miRNA) and small interfering RNA 
(siRNA). miRNA derives from small RNA regions that fold upon themselves to form small 
hairpin RNA (shRNA). siRNA stems from longer double stranded RNA (dsRNA) regions. For 
RNAi, first, dsRNA/shRNA gets processed into siRNA/miRNA by RNase enzymes called Drosha 
and Dicer. Second, siRNA/miRNA gets loaded onto the RNA-induced silencing complex (RISC), 
which unwinds the duplex and facilitates hybridization of siRNA/miRNA with a complementary 
mRNA strand. As a result, the targeted mRNA is silenced through one of two ways: (1) cleavage 
and degradation by an RNase called Argonaute or (2) inhibition of translation [94-97]. 
 
RNAi can also be induced experimentally and used to create a gene knockdown. Compared to 
a complete knockout, a gene knockdown silences a specific gene and reduces its expression, 
similar to how genetic variations associated with autoimmune disease present a reduced 
effect on gene expression. A gene KO typically requires embryonic stem cells (ESCs). 
Considering the technical difficulty of retrieving and maintaining ESC lines, another option is 
to cross breed KO animals with animals of the standard strain. This, however, is a very lengthy 
process with the potential of introducing other confounding variants. Alternatively, KD by 
RNAi is a viable and widely used method for studying the phenotype of certain risk alleles. 
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Gene KD can be achieved by the introduction of dsRNA or constructs which express shRNA 
and works both in vitro as well as in vivo. RNAi gene silencing can be used in almost any mouse 
strain or disease model. It is highly inducible and reversible, and it allows specific targeting of 
a single splice variant or sequence of only moderate silencing effect. However, it can be 
difficult to select a proper target sequence. Additionally, RNAi only causes a gene KD, which 
can be problematic when a certain phenotype only manifests after complete loss of the gene. 
Lastly, RNAi can lead to off-targeting, which is an unintended KD at an undesired location that 
can also potentially cause a measurable phenotype. This can be controlled for by using two 
independent shRNA sequences [94, 98]. Overall, RNAi is a valuable and widely accepted tool 
for studying autoimmunity-associated gene variants. 
 
 
Figure 8  Overview of the RNA interference pathway 
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(1.) Double stranded RNA molecules such as shRNA and pre-miRNA are cleaved and transported to the cytoplasm 
as short doubled-stranded fragments. (2.) siRNA and miRNA are separated into single strands and loaded onto 
the RISC. (3.) Single-strand fragments bind mRNA and block protein translation by (4.) either cleavage of mRNA 
or inhibition of translation. 
 
1.6.1. In vitro experiments with HeLa, HEK293T and MJC1 cells 
In vitro experiments are the basis of modern-day research. In vitro studies are performed on 
components of an organism, which are taken out of their original complex environment, to 
simplify a biological system and allow for a more detailed investigation of individual processes. 
Naturally, results of these studies can be difficult to translate back into the context of a whole 
organism. This can become even more problematic when working with cancer cells, which, by 
nature, show some form of transformation and therefore a phenotype that is not identical to 
the original organism. An advantage of in vitro studies is that they are highly specific. Human 
cells, for instance, can be studied directly without the need to rely on other organisms such 
as animal models. Due to their simplicity and reproducibility, in vitro studies have been 
optimized very well, which in turn offers great practicability and a high turnout of information. 
Here, in vitro work was performed on HeLa, HEK293T and MJC1 cells (see Chapter 2.1).  
 
1.6.2. In vivo studies with the NOD mouse 
In vivo studies are the pinnacle of today’s research as it allows for studies to be conducted 
within the living organism. Preferably, in vivo studies should be performed on humans as that 
is the relevant organism in clinical research. Most commonly, however, experimental animal 
models are used for in vivo research. Mouse models are the leading animal model for studying 
human disease. Mice are genetically and physiologically very similar to humans. Additionally, 
they are small and economically advantageous. Furthermore, mice can be genetically 
modified and inbred to create identical strains. Nevertheless, mouse models are less reliable 
to study human disease, than the human system itself. Naturally, animal studies are frequently 
discussed and questioned as their results have to be taken with caution. Regardless, the 
mouse model is an invaluable tool to further understand evolutionarily conserved 
mechanisms [99, 100]. For this project, the non-obese diabetic (NOD) mouse was used as the 
experimental model for in vivo studies.  
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2. Methods and Material 
2.1. HEK293T, HeLa and MJC1 cells 
Human Embryonic Kidney cells (HEK293) are derived from human kidney cells. They were 
initially transformed with adenovirus 5 and held in culture. Today, HEK293 are commonly used 
in research due to their reliable growth and aptitude for transfection. For this work, a highly 
transfectable cell line called HEK293T was used. These cells contain a mutant variant of the 
oncoprotein SV40 large T-antigen (TAg). Thus, DNA plasmids carrying the SV40 promoter get 
replicated in high numbers, which ensures a high turnout of viral protein [101]. 
 
HeLa are the most commonly used human cells in biomedical research. These cells were 
originally cervical cancer cells taken from a patient called Henrietta Lacks in 1951. They were 
the first cells to be “immortal”, meaning cells would not die after multiple divisions, and the 
first cells to be successfully cloned. To this day, HeLa can be used for a plethora of experiments 
with the boon of being a human cell line [102]. For this work, HeLa cells were transduced with 
lentivirus previously produced by HEK293T to create a gene KD through RNAi. The lentivirus 
carried plasmids encoding for shRNA that would be able to interfere with CLEC16A or ATG5 
sequences, respectively. 
 
MJC1 cells resemble cortical thymic epithelial cells. For the generation of MJC1, cells were 
retrieved from thymi of newborn mice and digested. Second, EpCAM+CD45- cells were sorted. 
Third, Ly-51+UEA1- cells were sorted and isolated as cTECs. MJC1 cells were used in this work 
to study the effect of impaired autophagy on TECs. These cells had kindly been generated by 
Dr. Mi-Jeong Kim and were provided by the Serwold Lab. 
 
All cells were grown in cell culture and sub-cultured for their respective experiments. Cells 
were microscopically checked regularly to ensure healthy growth and discarded at any sign of 
unnatural development. HEK293T cells were primarily used to produce shRNA lentivirus. HeLa 
and MJC1 cells were infected with lentivirus encoding neomycin resistance and shRNA 
targeting CLEC16A and ATG5 sequences (for HeLa), or puromycin resistance and shRNA 
targeting Clec16a and Atg5 sequences (for MJC1), respectively. The latter was performed by 
the Kissler Lab prior to this work. ATG5 plays an important role in the formation of 
autophagosomes [103] and therefore served as a positive control for impaired autophagy.  
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2.1.1.  Cell culture 
Cell cultures were kept and treated in aseptic environments. All cell lines were cultured in 
serum-positive media (500 ml DMEM with 10 % fetal bovine serum, 100 µg/ml 
penicillin/streptomycin, 2 mmol/l glutamine) and grown in 10 cm petri dishes at 37 °C and 5 
% CO2. Cells were split every one to three days at a confluency of 70-80 %. After discarding old 
media, the plate was washed with 10 ml DPBS. Cells were then lysed for 2-10 min using 2 ml 
0.05 % Trypsin-EDTA at 37 °C. To stop lysis and create a cell suspension, previously warmed 8 
ml serum-positive DMEM media were added. The cell suspension was then transferred to a 
10 ml tube and centrifuged at 1400 rpm for 4 min at 4 °C. After discarding the supernatant, 
the cell pellet was dissolved in 10 ml serum-positive DMEM. Depending on the desired 
dilution, 0.5 – 2 ml of the cell suspension was then transferred back onto a 10 cm petri dish 
and filled up to 10 ml with serum-positive DMEM.  
 
2.1.2.  Cell count 
Experiments were generally carried out with cells at a confluency of 70-80 % and a target 
count of approximately 2x106 (10 cm dish) cells or 0.3x106 (6-well plate) cells, respectively. 
Cells were washed, trypsinized and filled up to 10 ml with serum-positive DMEM (see 2.1.1). 
To count cells, 90 µl Trypan Blue were added to 10 µl of the cell suspension. 10 µl were taken 
from the mixture and then transferred to the counting chamber. Using a hand tally counter, 
living cells were counted in each of the 16 squares. To calculate the number of cells/ml, the 
average cell count (per square) was multiplied by 104 and then multiplied by 10 to correct for 
the 1:10 dilution. The targeted cell count in its respective volume was then transferred to 10 
cm petri dishes or 6-well plates and filled up with serum-positive DMEM.   
 
Table 1  Material for HEK293, HeLa, MJC1 
HEK293T Cells Joslin Diabetes Center 
HeLa Cells Joslin Diabetes Center 
MJC1 Cells Joslin Diabetes Center 
0,05 % Trypsin Gibco  
DMEM Gibco  
DPBS HyClone  
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Penicillin/Streptomycin Gibco  
Glutamine Gibco  
Fetal Bovine Serum Gibco  
Trypan Blue Solution Corning 
Counting Chamber Hausser Scientific  
Tissue Culture Dish Fisher Scientific 
 
2.1.3. Gene knockdown in HeLa 
2.1.3.1. Transformation of bacteria with CLEC16A and ATG5.7 DNA 
Transformation of bacteria is a process used to replicate plasmids by introducing DNA into a 
cell.  The CLEC16A and ATG5.7 plasmids also encoded for antibiotic resistance and were 
provided by the Kissler Lab. 25 µl NovaBlue Singles competent E. coli bacteria were thawed 
and mixed with approximately 1 µl plasmid (approximately 1 ng DNA) from the stock, which 
had previously been diluted with dH2O at a ratio 1:250. After 10 minutes of incubation on ice, 
the cell/DNA mixture was heat-shocked at 42°C for 30 seconds and then put back on ice for 
an additional 2 minutes. 30 µl of SOC medium were added to the tubes in order to obtain 
maximal transformation efficiency. The transformation was then spread on LB-Ampicillin agar 
plates and incubated overnight at 37 °C. Only bacteria successfully transformed were able to 
survive due to their inherent resistance to antibiotics. The next day, a single surviving colony 
was picked using a pipette tip and incubated in 5 ml LB-Ampicillin media shaking at 220 rpm 
for roughly 8 h at 37 °C.  
 
2.1.3.2. Plasmid preparation  
Bacteria were harvested the next day and centrifuged at 5000 rpm for 10 min at 4 °C. To 
extract DNA a Maxiprep Kit was used following the manual. Afterwards, DNA concentration 
was measured, which equaled 1.00 µg/µl for CLEC16A and 0.95 µg/µl for ATG5.7.  
 
2.1.3.3. shRNA lentivirus production for HeLa cells 
HEK293T cells were used as packaging cells to produce lentivirus encoding antibiotics 
resistance and shRNA. Depending on the plasmid, shRNA targeted CLEC16A, ATG5.7 or a 
luciferase gene which was not present in either human or mouse cells and served as a control. 
For lentivirus production, 10 µg DNA were added to an envelope mixture containing 1.75 µg 
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pCMV-VSV-G, 2.33 µg pMDLg/pRRE, 1.75 µg pRSV-Rev and 2.9 µg pAdv/TERT plasmids. 35 µl 
FuGENE and 600 µl serum-free DMEM were added per Eppendorf tube to transfect plasmid 
into the cells. The mixture was incubated for 30 min at room temperature (RT) and then added 
to HEK293T cells, which had been split 1:2 the day before.   
 
2.1.3.4. Transduction of HeLa cells with lentivirus  
Peak virus production is usually achieved 24 - 48 h post transfection. After 48 h at 37 °C and 
5% CO2, supernatant from the cells was centrifuged at 4000 rpm for 4 min at 4 °C to get rid of 
cell debris. Then, the supernatant was filtered using a 0.45 µm low protein-binding filters. At 
this point, the supernatant containing lentivirus could be used to transduce target cells and 
was mixed with media at a 1:1 ratio. HeLa cells on a 6-well plate were immediately transduced 
with 2 ml lentivirus mixture encoding antibiotics resistance and shRNA. The target sequence 
for CLEC16A in HeLa cells was GACTGATGATGTCCTGGATCTG. In MJC1 cells, two Clec16a KD 
lines were created with the target sequences CACCTTGTACGTCATTTCTATA (K3 line) or 
GAGTGTCCACCTTGTACGTCAT (K5 line). As the positive control, ATG5/Atg5.7 KD, the target 
sequence was GCAGAACCATACTATTTGCT. As the negative control, cells (HeLa and MJC1) were 
infected with lentivirus encoding for a puromycin resistance and shRNA of a luciferase not 
present in human or murine cells.  
 
2.1.3.5. Selection of successfully transfected HeLa cells 
The transfected DNA plasmid also contained a neo(R) gene. Neo(R) is a commonly used gene 
that encodes antibiotics resistance for neomycin and G418 (Geneticin) and serves as a 
selectable marker in cell biology. Only cells that were successfully transfected carried the 
vector including the neo(R) gene. After treatment with G418, vector(+) cells survived due to 
their antibiotics resistance, while vector(-) cells died in culture. The effective concentration of 
G418 varies greatly with different cell types. Therefore, the optimal concentration of G418 for 
selection was determined by titrating and treating HeLa cells with different concentrations of 
G418 ranging from 400 µg/ml to 1500 µg/ml. Cell survival was monitored microscopically over 
a 4-day period. At a concentration of 1500 µg/ml all non-transfected HeLa cells died, while 
lower concentrations did not sufficiently kill HeLa cells. Hence, 1500 µg/ml G418 were used 
for the selection of transfected HeLa-neo cells. After treatment with G418 over 9 days, the 
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remaining HeLa cells were considered to be vector(+) HeLa-neo cells. Over the course of these 
studies HeLa-neo cells were regularly (re-)treated with G418 to ensure purity.    
 
2.1.3.6. Validating knockdown efficiency by quantitative PCR 
Gene knockdown verification can be tested in multiple ways, for instance on the mRNA level 
via real-time PCR or the protein level via Western Blot. Methods such as real-time quantitative 
PCR (qPCR) have been shown to be efficient tools for verification of gene knockdown after 
siRNA gene silencing [104]. PCR is a commonly used technique based on thermal cycling and 
enzymatic replication of a specific DNA sequence. As a result, the template DNA is amplified 
exponentially and can be used for DNA quantification. With qPCR, amplification and detection 
of DNA are combined into one step and it is possible to quantify the target sequence in real 
time based on fluorescent dye staining. In this study, qPCR was used to detect knockdown in 
HeLa cells.  
 
As starting material, RNA was isolated from CLEC16A KD, ATG5.7 KD and control HeLa-neo 
cells using the High Pure RNA Isolation Kit following the manual. RNA was eluted with 30 µl 
RNase-free water. 0.88 µg RNA was then used to create cDNA with the SuperScript First-Strand 
Synthesis System following its manual step-by-step. cDNA was either stored at -20 °C or used 
for PCR immediately.  
 
This experiment aimed to measure mRNA expression levels of CLEC16A and ATG5.7 in HeLa 
cells. While RNA expression variation may be of biological cause, there is also a possibility of 
technical variance. To minimize technical variance and to normalize qPCR data, the 
ubiquitously expressed GAPDH gene was used as a reference gene, and standard operating 
techniques were used in all qPCR experiments. For qPCR, previously produced cDNA was 
diluted with dH2O at a ratio 1:20. For each sample, a master mix specific to the target 
sequence was created consisting of 1 µl forward primer, 1 µl reverse primer and 10 µl SYBR 
green. 8 µl of diluted cDNA were then plated on a 96-well plate before 12 µl master mix were 
added to a well. Wells purely filled with dH2O served as control. The plate was sealed, put on 
a vortex and centrifuged quickly before running the qPCR program. All data were analyzed 
using the software Graphpad Prism.  
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2.1.4. The OVA-LCR3 construct 
2.1.4.1. Transduction of MJC1 cells with dsRed-LC3 constructs 
To investigate the effect of impaired autophagy in TEC on the stimulation of OT-II thymocytes, 
the Kissler Lab had cloned a dsRed-LC3 fragment of a previously published dsRed-LC3-GFP 
construct [105]. The Kissler Lab had amplified it and incorporated a sequence for the OVA323-
339 peptide and reverse primers that would either leave LC3 intact or introduce a point 
mutation at position 120 that would switch in alanine for glycine. These fragments were then 
used to produce vectors encoding either dsRed-LC3 (control), dsRed-OVA-LC3 or dsRed-OVA-
LC3G120A (mutated) [106].  
 
For this thesis, lentiviral particles were produced for each plasmid combining 20 µg vector 
DNA, 3 µg pCMV-VSV-G, 4 µg pMDLg/pRRE, 3 µg pRSV-Rev and 5 µg pAdv/TERT. 70 µl FuGENE 
and 1200 µl serum-free DMEM were added to each Eppendorf tube. The mixture was 
incubated for 30 min at RT and then added to HEK293T cells, which had been split 1:3.5 the 
day before. After 48 h, the supernatant was retrieved, and the plates were checked for 
immunofluorescence to validate successful transfection. The supernatant was then 
centrifuged and filtered as mentioned in 2.1.3.4 before ultra-centrifuging at 25000 rpm for 90 
min at 4 °C. All supernatant was discarded and 100 µl PBS were added. The tube was stored 
at 4 °C overnight. The next day, the lentivirus was re-suspended in 100 µl PBS and added to 4 
ml serum-positive DMEM. Finally, 1 ml virus/DMEM mixture was added to MJC1 cells to create 
the desired cell lines.    
 
2.1.4.2. Sorting transduced MJC1 cells with flow cytometry 
Flow cytometry is a widely used technique to characterize and analyze cell subpopulations 
within a heterogeneous cell group. Cells can be analyzed by cell size and granularity or by the 
expression of cell surface proteins through fluorochrome staining. Three days after 
transfection, the MJC1 cells were sorted using a MACSQuant Analyzer depending on whether 
or not they were expressing dsRed. All data were analyzed with the software FlowJo. 
Approximately 200.000 cells of each cell line were retrieved as dsRed-positive cells and plated 
onto 24-well plates.  
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Table 2  Material for transformation and transfection 
NovaBlue Competent Cells Novagen 
CLEC16A, ATG5.7, CTRL plasmid Kissler Lab 
dH2O Gibco 
SOC Medium Invitrogen 
Eppendorf Safe-Lock Tubes Eppendorf 
Agar plates Kissler Lab 
LB-Ampicillin 
New Brunswich Classic C24 Incubator 
Kissler Lab  
New Brunswick Scientific 
NucleoBond Xtra Maxi Kit 
NanoDrop ND-1000 Spectrophotometer 
Macherey-Nagel  
NanoDrop Technologies 
pCMV-VSV-G Addgene 
pMDLg/pRRE Addgene 
pRSV-Rev Addgene 
pAdv/TERT Addgene 
FuGENE 
Millex-HV Syringe Filter Unit, 0.45 µg, 
PVDF, 33 mm, gamma sterilized 
Promega 
Millipore-Sigma 
G418 ThermoFisher Scientific 
High Pure RNA Isolation Kit Roche 
RNase free water Qiagen 
SuperScript First-Strand Synthesis Kit Invitrogen 
fwPrimer_CLEC16A 
rvPrimer_CLEC16A 
5’-CCTGATTTGGGGCGATCAAAA-3’ 
5’-CATAACGGCCTGATTTCTGCC-3’ 
fwPrimer_ATG5.7 
rvPrimer_ATG5.7 
fwPrimer_Actin Beta 1 
rvPrimer_Actin Beta 1 
5’-CACCCCTGAAATGGCATTATCC-3’ 
5’-TGGACAGTGTAGAAGGTCCTTT-3’ 
5’-GGCTGTATTCCCCTCCATCG-3’ 
5’-CCAGTTGGTAACAATGCCATGT-3’ 
fwPrimer_GAPDH 
rvPrimer_GAPDH 
5’-AGCTTGTCATCAACGGGAAG-3’ 
5’-TTTGATGTTAGTGGGGTCTCG-3’ 
Power SYBR Green ThermoFisher Scientific 
Prism software Graphpad 
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ABI 7900 Applied Biosystems 
dsRed-LC3, dsRed-OVA-LC3,  
dsRed-OVA-LC3G120A  
Kissler Lab 
MACSQuant Analyzer Miltenyi Biotec 
FlowJo Tree Star Inc. 
 
2.2. Detection of autophagy 
2.2.1. Initiation and inhibition of autophagy in HeLa 
Mammalian autophagy is a highly complex bulk degradation process that can be interfered 
with at a variety of steps. The most commonly studied trigger of autophagy is nutrient 
starvation.  Additionally, autophagy can be induced with Rapamycin [107]. In contrast, 
protease inhibitors such as Pepstatin A, E64d, Bafilomycin A1 and 3-Methyladenine (3MA) can 
be used to inhibit autophagy [107]. For this project, autophagy was induced by starvation. 
HeLa cells were washed with PBS and then incubated with 10 ml EBSS at 37 °C for different 
time spans ranging from 4 - 48 h. Controls were incubated with 10 ml serum-positive DMEM. 
Depending on the experiments, further chemical inhibitors or inducers were added, as 
mentioned above. In these cases, HeLa cells were treated with either a single drug or a 
combination of the following: E64d (10µg/ml), Pepstatin A (10 µg/ml), Bafilomycin A1 (50-100 
nM), 3MA (200 µM) or Rapamycin in different concentrations [108, 109].  
 
Table 3  Material for initiation and inhibition of autophagy in HeLa 
EBSS Gibco 
E64d Sigma 
Pepstatin A Sigma 
Bafilomycin A1 Sigma  
Rapamycin Invitrogen 
3-Methyladenine Sigma  
 
2.2.2. Immunoblot 
The immunoblot is a fast and highly sensitive assay for detection, quantification and 
characterization of proteins. Once extracted from tissue or cells, protein samples of equal 
amounts are loaded onto a gel and separated by electrophoresis depending on their 
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respective molecular size. Separated proteins are then transferred onto a nitrocellulose 
membrane. Here, the target protein is bound by a primary antibody, which in turn is bound 
by a secondary antibody linked to a reporter enzyme. The enzyme then reacts with a matching 
luminescent substrate. Light is emitted and captured on an autoradiography film. When 
detected, the target protein can be seen as a stained band.  
 
2.2.2.1. Preparing the lysates 
HeLa cells were centrifuged at 1400 rpm for 4 min at 4 °C and mixed with RIPA lysis buffer to 
lyse cells and extract proteins. Cells were put on ice for 15 min and then centrifuged at 16000 
g for 10 min at 4 °C to get rid of cell debris. 5 µl supernatant and 5 µl lysis buffer were mixed 
with 150 µl Pierce 660 nm Protein Assay Reagent and incubated for 5 min at RT. The 
absorbance of all samples was measured at 660 nm with the Synergy Mx Microplate Reader. 
As controls, 10 µl lysis buffer were mixed with 150 µl Pierce 660 nm Protein Assays Reagent. 
The average absorbance of the controls was subtracted from the individual absorbance of 
each sample. Protein concentration was calculated using the Bovine Serum Albumin (BSA) 
standard curve. All samples were diluted with 4x Laemmli buffer at a ratio 3:1 and cooked for 
3 min at 95 °C. Samples were then either stored at -20 °C or used immediately.   
 
2.2.2.2. SDS-PAGE 
Sodium dodecyl sulfate (SDS) binds entire peptide backbones with its negative charges and 
negates the protein’s intrinsic charge, conferring equal charge for every protein. Based on this, 
proteins can simply be separated by mass after application of an electric field in SDS-PAGE. 
The SDS-PAGE gel is divided into a separating gel and a stacking gel. The percentage of 
acrylamide depends on the molecular weight of the target protein. Given the molecular 
weight of LC3 (15 kD), p62 (47 kd) and actin (42 kD) a 12 % acrylamide gel was generally used 
for the experiments. The separating gel was produced by mixing 3.2 ml dH2O with 4.0 ml 30 
% acrylamide, 2.6 ml 1.5 M Tris-HCl (pH 8.8) and 100 µl 10 % SDS in a small beaker. 
Immediately before pouring the gel, 10 µl TEMED and freshly made 100 µl 10 % APS were 
added to the mixture. The thoroughly mixed solution was then pipetted between two 1.0 mm 
spacer plates held by the casting frame. H2O was added to make the top of the gel horizontal. 
The separating gel solidified within 20 - 30 min. After discarding the H2O, the stacking gel was 
pipetted onto the separating gel and a 12-well or 15-well comb was inserted. The 4 % stacking 
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gel was made by mixing 2.975 ml H2O with 670 µl 30 % acrylamide, 1.25 ml 0.5 M Tris-HCl (pH 
6.8) and 50 µl 10 % SDS. Before pouring the gel, 5 µl TEMED and freshly made 50 µl 10 % APS 
were added to the mixture. The stacking gel solidified within 20 - 30 min. Gels were either 
used immediately or stored at 4 °C wrapped in wet paper towels and sealed for no longer than 
one week. For electrophoresis, gels were loaded with equal amounts of protein ranging from 
10 – 30 µg consistent within each respective experiment. Samples were cooked at 95 °C for 5 
- 10 min before electrophoresis. Additionally, 8 µl protein marker were loaded onto the first 
lane. Proteins were then separated using a buffer-filled mini-PROTEAN Tetra Cell system 
running at 80 - 120 V until the migration front reached the bottom of the gel.   
 
2.2.2.3. Western Blot 
After separation by SDS-PAGE, proteins were transferred from the gel to a nitrocellulose 
membrane using a Mini Trans-Blot Electrophoretic Transfer Cell. For transfer, gel and 
membrane were sandwiched (from cathode to anode: foam pad, filter paper, gel, membrane, 
filter paper, foam pad) in 4 °C transfer buffer, ensuring no bubbles had formed between gel 
and membrane. The gel-membrane sandwich was then placed within the Transfer Cell and 
submerged in 4 °C transfer buffer. To create an electrical field, 75 V were applied for 60 min 
at 4 °C. Within this field, all negatively charged proteins moved towards the anode and were 
bound by the membrane. Experiments were continued only if successful transfer was visually 
confirmed.  
 
2.2.2.4. Immunodetection 
To prevent unspecific binding of the primary or secondary antibody to the membrane, TBS/T 
5 % Milk (1 % Tween, 5 % milk powder) was used to block the membrane. For this, the 
membrane was placed on a shaker for 30 min at 40 Hz and RT. While washing the membrane 
with TBS/T for 5 min, the primary antibody was prepared. The primary antibody was diluted 
in TBS/T at a 1:500 ratio (LC3, p62, ACTIN) or 1:250 (CLEC16A, DEXI), respectively. Membranes 
were cut and placed in sealed plastic for individual incubation, before adding the primary 
antibody. At 4 °C, the primary antibody was constantly agitated and incubated overnight. The 
next day, all membranes were washed several times in TBS/T for 5 min per wash to remove 
residual primary antibody. After washing, secondary antibodies were diluted at 1:5000 (anti-
mouse for ACTIN, anti-rabbit for LC3, P62 and CLEC16A), added to the membranes and 
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incubated for 1 h rocking at 40 Hz and RT. After incubation, the membranes were washed in 
TBS/T three times for at least 5 min per wash. All secondary antibodies were conjugated with 
horseradish peroxidase as a reporter enzyme, which would react with 1 ml 1:1 chemilumiscent 
stubstrate that was added to each membrane. The membranes were placed into an 
autoradiography cassette. In the dark room, an autoradiography film was placed inside the 
cassette and exposed, ranging from 10 s to 15 min, before being developed.   
 
2.2.2.5. Data analysis 
To quantify the amount of expressed protein, autoradiography films were scanned in 16-bit 
grayscale and 600 dpi. Pixel intensity was then analyzed in ImageJ64 and data was presented 
with Graphpad Prism.  
 
Table 4  Material for immunoblotting 
RIPA lysis and extraction buffer Thermo Scientific 
Pierce 660 nm Protein Assay Reagent Thermo Scientific 
Synergy Mx Microplate Reader Biotek 
4x Laemmli Buffer Bio-Rad  
30 % Acrylamide Bio-Rad 
1.5 M Tris-HCl, pH 8.8 Bio-Rad  
0.5 M Tris-HCl, pH 6.8 Bio-Rad 
10 % SDS Bio-Rad  
TEMED Bio-Rad  
APS Bio-Rad  
1 mm / 1.5 mm spacer plates Bio-Rad  
12-well / 15-well comb Bio-Rad  
mini-PROTEAN Tetra Cell System Bio-Rad  
PowerPac Basic Power Supply Bio-Rad  
Precision Plus Protein Standard  Bio-Rad  
Running Buffer  Kissler Lab  
mini Trans-Blot Cell  Bio-Rad  
Foam Pads  Bio-Rad 
Blot Absorbent Filter Paper Bio-Rad 
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Nitrocellulose membrane  Bio-Rad 
Transfer Buffer  Kissler Lab  
Milk Powder  Fisher Scientific 
Tween Fisher Scientific 
TBS Kissler Lab  
Mini Rocker  Bio-Rad 
β-ACTIN Antibody  Santa Cruz  
LC3B Antibody  Santa Cruz 
P62 Antibody  GeneTex 
CLEC16A Antibody  Novus Biologicals 
DEXI Antibody  Novus Biologicals 
Anti-Rabbit IgG HRP-linked GE Healthcare UK 
Anti-Mouse IgG HRP-linked GE Heathcare UK 
Chemiluminescent Substrate  Fisher Scientific 
Autoradiography Cassette   Fisher Scientific 
Autoradiography Film  Fisher Scientific 
X-Ray Machine  Konica Minolta 
Scanner  HP 
ImageJ64  NIH 
 
2.3. The NOD Clec16a KD Mouse 
The most prominent experimental animal model for studying T1D is the non-obese diabetic 
(NOD) mouse model. The NOD strain was created almost 40 years ago as a descendant of a 
cataract-prone strain [110]. Since then, the NOD mouse has been established as an excellent 
model for human autoimmune diabetes (T1D) as well as other autoimmune diseases. The 
power of the NOD strain is that it develops spontaneous autoimmune diabetes very similar to 
the human T1D, with autoreactive CD4+ and CD8+ cells and autoantibodies [111]. Antigens 
recognized by autoreactive T cells in human and NOD mice include insulin, GAD, IA-2 and the 
heat shock protein 60 (Hsp60) [112]. Similar to T1D in human, diabetes in NOD mice is a 
polygenetic disorder, as there are multiple gene loci linked to susceptibility. One major 
contributor to genetic susceptibility in this strain is the MHC haplotype called H-2g7 [113], 
which affects T cell selection directly. There are other contributors, too, such as a defective 
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system of macrophages and natural killer cells. Furthermore, autoantibodies against antigens 
such as insulin and GAD can be found in NOD animals [114]. Nonetheless, autoimmune 
diabetes in the NOD strain is mostly dependent on autoreactive CD4+ and CD8+ cells. Evidently, 
disease can be induced by transfer of purified CD4+ and CD8+ cells and inhibited by alteration 
of T cells, whereas transfer of autoantibodies does not seem to induce autoimmune diabetes 
[111]. 
 
Generally, onset of spontaneous autoimmune diabetes in the NOD mouse occurs at 12 – 14 
weeks of age [111]. Female NOD mice show a higher incidence rate of approximately 80% 
compared to males with an incidence rate of 20 – 30% [115, 116]. At 3 – 7 months of age, 80% 
of female NOD animals and 50% of male NOD animals demonstrate insulin dependency [113]. 
Histologically, as early as 3 – 4 weeks of age, NOD mice show lymphocytic infiltrates 
surrounding pancreatic islets (peri-insulitis). Later, at approximately 10 weeks of age, these 
infiltrates afflict the pancreatic islets and cause severe insulitis, similar to T1D in humans [111, 
117]. 
 
Prior to this work, Clec16a KD NOD mice had been generated by the Kissler Lab [106]. In 
summary, Clec16a KD was generated by the Kissler Lab via lentiviral transgenesis. For this, 
lentivirus encoding for shRNA and a GFP reporter was injected into NOD zygotes. For the K3 
KD line, the pLBM vector [118] was used with its target sequence 
CACCTTGTACGTCATTTCTATA. K5 KD mice were generated with a pUGM vector and 
GAGTGTCCACCTTGTACGTCAT as the target sequence. Successful KD was checked by GFP 
expression levels. All KD animals were kept as homozygous, GFP positive animals. As a control 
group, WT NOD mice were used. OT-II TCRα-/- mice were provided by the Serwold Lab [106]. 
Mice were held in the animal facility of the Joslin Diabetes Center and treated appropriately 
under Animal Welfare Rules and Regulations. Experimental procedures on animals were 
approved by the Institutional Animal Care and Use Committee.  
 
2.3.1. Levels of gene expression in tissue 
To study the expression and co-expression of Clec16a and its neighboring genes located on 
the 16p13.3 locus, different murine tissues were collected and used for qPCR.   
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2.3.1.1. Collecting and preparing organs 
For each experiment, three mice (n=3) were used of each genotype (K3, K5 and WT), 
consistent within all experiments. Mice were euthanized, using CO2 to provide a painless, 
rapid and stress-free death. Then, the animals were pinned down and dissected using micro-
dissection scissors and tweezers. To reach the cranial, thoracic and abdominal cavity, fur and 
skin were dissected and rib cage and skull were opened carefully. The desired organs were 
cautiously prepared without damaging tissue or vessels. Tissue samples were collected from 
thymus, heart, inguinal lymph nodes, spleen, pancreas, liver, kidney and brain. After 
collection, organs were homogenized in TRIzol and stored at -80 °C for further use.  
 
2.3.1.2. RNA extraction from organ tissue  
After thawing the organ samples, 200 µl Chloroform and 1 ml TRIzol were added. The tubes 
were shaken vigorously, incubated for 2 min at RT and centrifuged at 12000 g for 15 min at 4 
°C. The upper aqueous supernatant was collected and transferred to a new tube. 500 µl 
isopropanol and 1 ml Trizol were added, before shaking again for 15 sec, incubating for 10 min 
at RT and centrifuging at 12000 g for 10 min at 4 °C. The supernatant was retrieved and 
washed with 1 ml 75 % ethanol. The sample was spun at 7500 g for 5 min at 4 °C and air-dried 
for 5 min. Pellets were re-suspended in dH2O and placed on a shaker for 15 min at 37 °C. RNA 
concentrations were then measured using the NanoDrop machine.   
 
2.3.1.3. Islets isolation 
Murine pancreatic islets were isolated according to a slightly modified protocol [119]. After 
sacrificing the animals, a V-incision was made to open the abdominal cavity. Bowel and liver 
were moved to the side cautiously to expose the pancreas and the common bile duct (CBD). 
Bulldog Clamps were placed on both sides of the duodenum. The gall bladder was punctured 
with a 1 ml syringe and collagenase solution (HBSS, 10 % FCS, 0.5 mg/ml collagenase) was 
applied to the CBD in order to distend the duct. The CBD was then catheterized with a 10 ml 
syringe and 3 ml collagenase solution were injected into the pancreas. When done correctly, 
the pancreas would assume more than three times its original size. The pancreas was removed 
and placed in a pre-cooled falcon tube containing 1 ml collagenase solution. After organ 
harvest, the falcon tubes were incubated at 37 °C for 17 min and shaken to dissolve the 
pancreas. 12 ml washing solution (HBSS + 10 % FCS) were added and the mix was flushed 
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through the cell strainer. All samples were centrifuged at 4 °C until the centrifuge reached 
1500 rpm, then the supernatant was carefully discarded. After repeating this step twice, the 
pellet was re-suspended with 5 ml Histopaque-1077. 10 ml washing solution were carefully 
added without disturbing the gradient. All samples were centrifuged at 2400 rpm for 10 min 
with the break turned off. At this point, pancreatic islets could be identified as the layer 
floating between the Histopaque-1077 and the washing solution. All islets were carefully 
aspirated and transferred into a new falcon tube. Again, samples were centrifuged at 4 °C until 
the centrifuge reached 1500 rpm and the supernatant was carefully discarded. The pellet was 
re-suspended in 200 µl PBS and 400 µl Lysis/Binding Buffer and the samples were stored at -
80 °C. For RNA extraction, the High Pure RNA Isolation Kit was used according to the manual 
as previously described in chapter 2.1.3.6.  
 
2.3.1.4. Measuring gene expressing with qPCR  
RNA was isolated from murine pancreatic islets and other murine tissue. 1.00 µg RNA was 
used to create cDNA and qPCR was performed as previously described (chapter 2.1.3.6.), with 
-Actin as the reference gene, to measure mRNA expression levels of Clec16a and its 
neighboring genes Dexi, Socs1 and CIIta.  
 
Table 5  Material for measuring gene expression in organ tissue 
NOD mouse Joslin Diabetes Center 
CO2 Joslin Diabetes Center 
Ethanol Fisher Scientific 
Micro-Dissection Scissors Biomedical Research Instruments 
Tweezers Biomedical Research Instruments 
TRIzol Reagent Fisher Scientific 
TissueLyser II Qiagen 
Chloroform Fisher Scientific 
Isopropanol Sigma-Aldrich 
Bulldog Clamp Biomedical Research Instruments 
Syringe 1 ml, 10 ml  Sigma-Aldrich 
HBSS, 10 % FCS Gibco 
Collagenase Fisher Scientific 
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Histopaque-1077 Sigma-Aldrich 
Lysis/Binding Buffer Fisher Scientific 
  
2.3.2. Intraperitoneal glucose tolerance test 
The intraperitoneal glucose tolerance test is used to study metabolic function by measuring 
glucose clearance after intraperitoneal injection of glucose. For this experiment, six animals 
of each genotype (K3, K5 and WT) were matched by sex, weight and age.  Mice were fasted 
for 16 h overnight with no access to food, but with a sufficient supply of water. All mice were 
weighed for baseline body mass. A 20 % glucose solution (2 g glucose / kg body weight, in PBS) 
was prepared and the volume for intraperitoneal injection was calculated: V (µl) = 10 x body 
weight (g). To measure blood glucose levels, mice were restrained with their tail exposed. The 
tip of the tail was scratched with a sterilized scalpel and a drop of blood was placed on the 
test strip of the blood glucose meter. The first sample was taken at t = 0 min and recorded as 
the baseline value. After the first measurement, the abdominal area was washed with 70 % 
ethanol. The animal was grabbed firmly by the back and glucose solution was injected 
intraperitoneally with a sterile needle at an angle of approximately 45 ° near the ventral axis, 
avoiding epigastric vessels and away from liver and kidneys. Blood glucose levels were then 
measured, as described above, at t = 15, 30, 60, 90 and 120 min. Data was presented as a 
depiction of blood glucose levels over time after intraperitoneal injection.  
 
Table 6  Material for the intraperitoneal glucose tolerance test 
Beta-D-Glucose Sigma Aldrich 
ACCU-CHEK Aviva ACCU-CHEK 
ACCU-CHECK test strips ACCU-CHEK 
Single-Use Needles BD Medical 
Animal Weighing Scale Kent Scientific 
 
2.3.3. Insulitis Score 
To investigate the lymphocytic infiltration of pancreatic islets in Clec16a KD and WT animals, 
pancreata of female NOD mice were collected at 4, 6, 8 and 10 weeks of age and frozen in OCT 
Compound by the Kissler Lab. Pancreatic tissue was cut into 7 µm cryosections and stained 
with hematoxylin and eosin. The degree of lymphocytic infiltration was studied with a light 
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microscope and pancreatic islets were scored as having no infiltration, moderate infiltration 
or severe infiltration [120].  
 
2.3.3.1. H.E. Staining 
Cryosections were washed in PBS before staining with hematoxylin for 1 min. Sections were 
rinsed with water and hematoxylin was fixed in acid water. After rinsing with water, sections 
were dunked in 0.2 % Ammonium Hydroxide Solution. After washing with water, sections 
were rinsed with 95 % ethanol and stained with Eosin Y for 30 s.  Dehydration was performed 
in 95% (twice) and 100 % (thrice) Ethanol. Slides were preserved in Xylene, mounted with 
Cytoseal 60 medium and covered with cover slips. Images for analysis were acquired using a 
light microscope equipped with a digital camera. 
 
2.3.3.2. Scoring pancreatic islet inflammation 
2 - 5 animals of each genotype and age combination were used for the experiment. Six 
sections per pancreas were manually analyzed and over 3500 islets were scored in total. 
Insulitis was scored as no infiltration, moderate infiltration (peripheral, or < 50 % of the islet) 
and severe infiltration (>50 % of the islet) [120]. Data was manually tallied and analyzed.  
 
Table 7  Material for insulitis scoring 
Beta-D-Glucose Sigma Aldrich 
ACCU-CHEK Aviva ACCU-CHEK 
ACCU-CHECK test strips ACCU-CHEK 
Single-Use Needles BD Medical 
Animal Weighing Scale 
Light Microscope 
Digital Camera 
Kent Scientific 
Zeiss 
Olympus 
 
2.3.4. Thymic Transplantation  
To show that the effect of Clec16a KD was specific to the thymus, NOD WT mice were 
thymectomized and irradiated, then reconstituted with lineage-depleted NOD WT bone 
marrow cells and transplanted with either NOD WT or Clec16a KD E14 thymic lobes. 
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Cyclophosphamide was injected to accelerate disease onset. Animals were then regularly 
monitored for glycosuria.  
 
 
Figure 9  Thymic transplantation, schematic overview 
Thymectomized NOD WT mice of 4 weeks of age were purchased from Jackson Laboratory. Subsequently, mice 
were irradiated and reconstituted with NOD WT lineage-cell depleted bone marrow by members of the Kissler 
Lab. 2 weeks later, thymic transplantation was performed as part of this thesis and E14 lobes were transplanted 
under the kidney capsule. 6 weeks later cyclophosphamide was injected to accelerate onset of diabetes. Thrice 
per week mice were tested for glycosuria.  
 
2.3.4.1. Thymectomy and irradiation 
Thymectomies were performed on NOD WT mice at 4 weeks of age by Surgical Services at 
Jackson Laboratories. The animals were subsequently irradiated at 900 rad by members of the 
Kissler Lab to eliminate endogenous hematopoietic cells and prepare for bone marrow 
transplantation. 
 
2.3.4.2. Generation of bone marrow chimeras   
To retrieve donor bone marrow, NOD WT donor mice were euthanized. The animals were 
dissected using forceps and scissors. Tibia and femur bones were removed, rinsed in 70 % 
ethanol and collected in cold PBS. Excess muscle and other tissue were removed, and the ends 
of the bones were cut off. Tibial and femoral shafts were flushed using a syringe with a 29G x 
½ needle and bone marrow cells were collected. Bone marrow cells were pooled, and the 
density was adjusted to 5 x 106 / ml PBS. A MACS lineage depletion kit was used by members 
of the Kissler Lab to retrieve lineage-depleted BM cells. 200 µl of lineage-depleted BM cells 
were then injected intravenously into irradiated recipient mice.  
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2.3.4.3. Preparation of E14 thymic lobes 
Pregnant donor mice were euthanized and sprayed with 70 % ethanol. The abdominal wall 
was cut and the peritoneum severed to reveal the uterus. The uterus was then separated from 
ligaments, removed from the abdominal cavity, transferred to a petri dish and cut lengthwise 
to expose and remove all embryos. Under the dissecting microscope, embryos were operated 
on and thymic lobes were collected in media.   
 
2.3.4.4. Transplantation of E14 thymic lobes 
After two weeks, the previously thymectomized BM chimeric recipient mice were 
anaesthetized with isoflurane. After anaesthetics had taken effect, the left flank was shaved. 
The skin was swabbed with iodine and wiped with 70 % Ethanol. After locating the left kidney 
underneath the skin, a small incision was made to expose the peritoneum. The peritoneum 
was opened carefully with an incision, keeping the incision small enough to prevent the 
exposed kidney from sliding back into the abdominal cavity. By pushing on both sides of the 
incision, the kidney was elevated and popped out of the abdomen. Kidneys were constantly 
kept moist using saline solution and fixated through clamps on each side of the incision. Using 
a 23G needle, the kidney capsule was then carefully scratched to create a small opening in the 
tissue. The embryonic thymus was placed in the opening and carefully pushed underneath the 
remaining capsule using forceps. Minimal bleeding was stopped using a dry cotton tipped 
swab. After re-moistening, clamps were removed, and the kidney was carefully placed back 
into the abdominal cavity. The peritoneum was closed using 5-0 silk sutures. Skin was pulled 
together and stapled two to three times. After the procedure, mice were placed underneath 
a heating lamp until full recovery.  
 
2.3.4.5. Diabetes frequency study 
Six weeks after surgery, all mice were injected with 200 mg/kg cyclophosphamide 
intraperitoneally to accelerate disease progression. Onset of diabetes was monitored 
regularly thrice per week by measuring glycosuria using Diastix. Mice with consecutive glucose 
levels of more than 250 mg/dL were considered diabetic.  
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Table 8  Material for thymic transplantations 
thymectomized NOD mice 
43855F Cabinet X-ray System – CP160 
Option 
Jackson Laboratories 
Faxitron X-ray Corporation 
Standard scissors Kent Scientific 
Dissecting forceps, tissue forceps Kent Scientific 
Syringe with 29 G x ½ needle Fisher Scientific 
23G needle Fisher Scientific 
MACS lineage depletion kit 
Brooder Heat Lamp – Model GP095B 
Miltenyi Biotec 
Brooder 
Dissecting microscope Fisher Scientific 
Animal clipper 
Cotton swaps 
Braintree Scientific 
CVS 
Iodine solution Fisher Scientific 
Scalpel handle and blades Kent Scientific 
Micro Bulldog clamp Kent Scientific 
Saline solution Jackson Laboratories 
Silk sutures Jackson Laboratories 
Stapler and staples Jackson Laboratories 
Diastix Jackson Laboratories 
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3. Results 
The following chapter partially contains data compiled and analyzed by Dr. Cornelia Schuster 
and Prof. Dr. Stephan Kissler (both members of the Kissler Lab, who supervised the author of 
this thesis), which was generated for the manuscript “The autoimmunity-associated gene 
CLEC16A modulates thymic epithelial cell autophagy and alters T cell selection” (Immunity, 
2015, Schuster et al.). That data served as a foundation and framework for this thesis, and 
thus provides necessary context for the experiments and sub-experiments that were 
performed by the author of this thesis. Hence their inclusion in the following chapter. Data 
or figures generated by members of Kissler Lab will be marked with an asterisk (*) to clearly 
separate them from the work specifically done by the author of this thesis.   
  
3.1. In vivo results 
3.1.1. * Clec16a knockdown protects NOD mice from autoimmune diabetes 
To study the role of CLEC16A in the pathogenesis of T1D, the Kissler Lab had generated a 
Clec16a KD NOD mouse model prior to this work (see Chapter 2.3). Lentiviral transgenesis had 
been used to introduce shRNA and a reporter GFP into the animals. GFP expression levels 
were checked in all animals to validate transgene expression (data not shown) [106]. Figure 1 
is exemplary of various methods used by the Kissler Lab to validate an effective gene KD. As 
an example, there were significantly decreased expression levels of Clec16a mRNA in the 
spleen of KD animals relative to WT animals (Figure 1A). Furthermore, significantly reduced 
protein expression levels of Clec16a were found in the thymus of KD animals compared with 
WT animals (Figure 1B), as well as the spleen (data not shown).  
 
 
Figure 10  * Clec16a knockdown efficiency in NOD mice, as published by Schuster et al.  
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(A) Relative expression of Clec16a mRNA in the spleen of WT and K3 KD mice. Significant reduction of mRNA 
expression levels in KD animals. *** p < 0.001, two-tailed t-test, data representative of 5 experiments. (B) 
Western Blot with -actin as loading control. Clec16a protein levels in the thymus of WT (n = 3) and KD (n = 3) 
animals. Significant reduction of protein levels in KD animals. * p < 0.05, two-tailed t-test, similar results in spleen 
(not shown) [106]. 
 
Transgenic mice developed expectedly with no visual change in phenotype. Most remarkably, 
however, Schuster et al. could demonstrate that Clec16a KD NOD animals were almost 
completely protected from autoimmune diabetes. To study disease protection, diabetes 
frequency studies were performed as described in Chapter 2.3.4.5. Briefly, blood glucose 
levels in animals were monitored regularly and diabetes was diagnosed when blood glucose 
levels were higher than 250 mg/dL in two consecutive measurements.  As seen in Figure 2A, 
almost no Clec16a KD NOD mice suffered from autoimmune diabetes, while more than 60% 
of WT animals developed disease. Similar results were found after diabetes induction was 
accelerated via cyclophosphamide (CY) in Clec16a KD animals vs. WT animals [121] (data not 
shown). To see whether disease protection could be mediated by the immune system, 
Schuster et al. transferred splenocytes into immunodeficient NOD.SCID [122] mice which 
lacked both T and B lymphocytes. After transferring splenocytes from WT and Clec16a KD 
animals into NOD.SCID mice, animals injected with Clec16a KD splenocytes were indeed 
protected from CY induced diabetes (Figure 2B). Contrary, as displayed in Figure 2C, transfer 
of WT splenocytes into Clec16a KD NOD.SCID reinstated disease susceptibility, suggesting a 
protective effect of transgenic lymphocytes as opposed to changes in the pancreatic tissue. 
Specifically, the Schuster et al. identified the transgenic T cell population as the mediator of 
disease protection by reconstituting NOD.SCID animals with transgenic B and T lymphocytes 
and only seeing disease protection limited to mice which were injected with transgenic T cells 
(Figure 1D) [106].  
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Figure 11  * Clec16a knockdown protects from autoimmune diabetes due to less diabetogenic T 
lymphocytes, as published by Schuster et al.  
(A) Diabetes frequency study in WT (n=50) and Clec16a KD (n=42) animals. Significantly more KD animals are 
protected from diabetes, p <0.01. (B) Diabetes frequency study induced by CY in NOD.SCID mice reconstituted 
with splenocytes of WT (n=16) or Clec16a KD (n=18) animals. Significant protection of disease after injection with 
KD splenocytes, p <0.01. (C) Diabetes frequency study in WT NOD.SCID (n=13) vs. Clec16a KD NOD.SCID (n=14) 
mice reconstituted with WT splenocytes with no difference in disease frequency p = 0.36, Fisher’s exact test. (D) 
Diabetes frequency study, induced by CY, in NOD.SCID mice reconstituted with T and B lymphocytes in the 
following combinations WT/WT, WT/KD, KD/KD and KD/WT, respectively. Significant disease protection in both 
animal groups injected with KD T cell groups, p < 0.01. For A, B and D data were analyzed using the Log-rank test. 
[106]. 
 
3.1.2. Clec16a silencing diminishes the severity of insulitis in pancreatic islets in NOD mice  
After establishing that T cells were less diabetogenic in Clec16a KD mice, this project aimed to 
investigate whether there was a visible microscopic change in pancreatic islet inflammation. 
As described in Chapter 1.1.2, insulitis is a characteristic feature of autoimmune diabetes. To 
study inflammation of pancreatic islets in WT and Clec16a KD animals, lymphocyte infiltration 
was microscopically scored in pancreata of female NOD mice of each genotype (Chapter 
2.3.3). Insulitis phenotype was manually scored and classified into three groups depending on 
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the level of lymphocyte infiltration. Figure 3 shows one example of each grade of insulitis in a 
WT NOD mouse, ranging from ‘no insulitis’ to ‘severe insulitis’.  
 
 
Figure 12  Insulitis subgroups in the NOD WT mouse 
Microscopic scoring of insulitis in an exemplary female WT NOD mouse at 8 weeks of age. Pancreatic sections 
were 7 µm thick and stained with hematoxylin and eosin. Six sections (approximately 90 islets) were scored per 
animal. Insulitis was divided into three subgroups: no insulitis (left panel), moderate insulitis with <50 % 
lymphocyte infiltration or peripheral infiltration (middle panel) and severe insulitis with >50 % lymphocyte 
infiltration or central infiltration (right panel). Above, lymphocytes can be identified as small cells with spherical 
nuclei and an abundance of dark-staining chromatin (purple), and very little cytoplasm.  
 
To see if Clec16a KD had any effect on the quality and severity of insulitis, pancreatic tissue 
samples of WT and Clec16a KD NOD mice were collected at four different developmental 
stages ranging from 4 to 10 weeks of age. There was no change in macroscopic pancreatic 
structure, weight and size. Also, there were no significant differences in number or size of 
pancreatic islets (data not shown). Overall, all stages of insulitis were found in both WT and 
Clec16a KD animals. Similar to insulitis in human, some pancreatic islets showed no signs of 
inflammation in WT NOD and Clec16a KD mice (Figure 4, left panels). Figure 4 shows the 
typical distribution of the varying stages of insulitis in WT NOD and Clec16a KD mice at 4, 6, 8 
and 10 weeks of age. Strikingly, Clec16a KD reduced the severity of insulitis. Islet inflammation 
was more prominent in WT NOD mice with an earlier onset of insulitis as well as a more severe 
infiltration of lymphocytes at all stages of age, most prominently at 8 and 10 weeks of age. As 
seen in Figure 4, Clec16a KD delayed the onset of insulitis and reduced the severity of 
inflammation drastically.  
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Figure 13  Clec16a knockdown delays onset and reduces severity of insulitis in the NOD mouse 
Pancreatic islets of WT NOD and Clec16a K3 NOD mice at 4, 6, 8 and 10 weeks of age, stained with hematoxylin 
and eosin. Lymphocytes can be identified as small cells with little cytoplasm and an abundance of dark-staining 
chromatin. n = 2 – 5 animals were used for each age group. Six pancreatic sections per animal were analyzed 
manually. Approximately 10 – 15 islets were analyzed per section, n = 120 – 450 per age group. Shape and size 
of pancreas, as well as severity (stage) and onset of lymphocyte infiltration was studied. There are no differences 
in shape of pancreatic islets. (Top panels): Early onset of insulitis (6 w) in WT animals with severe inflammation 
(10 w), increasing with age. (Bottom panels): Delayed onset of insulitis in Clec16a KD animals with significantly 
less infiltration of lymphocytes (see Figure 5), even at high age. Displayed results are representative of K5 animals 
(second Clec16a KD line), with n = 2 – 5 animals and n = 120 – 450 islets, data not shown.  
 
In addition to studying the quality of insulitis in WT and Clec16a KD animals, inflammatory 
lesions were also quantified in the same experiment. Overall, more than 3500 islets were 
analyzed and counted in a total of 24 animals. Figure 5 shows the distribution of the three 
stages of insulitis in WT NOD and Clec16a KD mice (pooled data from K3 and K5). With rising 
age, there was an increase in both moderately and severely inflamed islets in both groups. 
This increase was significantly greater in WT NOD mice, as the two insulitis stages became 
more prevalent at higher age. Strikingly, while the frequency of inflamed islets steadily 
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increased with age in WT NOD mice to a prevalence of up to 60 % at 10 weeks of age, the 
frequency of inflamed islets in Clec16a KD mice remained unchanged at approximately 15 %. 
Even after 10 weeks, up to 85 % of islets in Clec16a KD mice showed no sign of inflammation. 
While WT NOD mice suffered from an increased severity and rate of insulitis with older age, 
Clec16a KD mice were mostly protected from insulitis.  
 
 
Figure 14  Clec16a knockdown results in significantly less insulitis lesions in the NOD mouse 
Rate of Insulitis in WT NOD and Clec16a KD mice at 4, 6, 8 and 10 weeks of age. n = 60 – 90 islets per animal, n = 
120 – 450 islets per age/genotype group, total islets analyzed n = 3600 – 4000. (Left panel): significantly increased 
rate of insulitis (moderate + severe) in WT animals of 4 weeks vs. 10 weeks of age, with 60% of all islets inflamed 
at 10 weeks of age, ** p < 0.01, two-tailed t-test. (Right panel): Significantly reduced rate of insulitis (moderate 
+ severe) in Clec16a KD animals of 10 weeks of age vs. WT animals of 10 weeks of age, ** p < 0.01, two-tailed t-
test.  
 
3.1.3. * Clec16a knockdown causes T cell hyporeactivity  
Further characterization of transgenic T lymphocytes in Clec16a KD animals by Schuster et al. 
is displayed in Figure 6 [106]. For this, proliferation rates of T cells were measured using a 
thymidine incorporation assay that quantified the amount of 3H-thymidin which was 
incorporated into new DNA strands during mitotic cell division. After stimulation of the TCR 
with CD3 antibody, polyclonal CD4+ T cells in Clec16a KD animals showed less 3H-thymidin 
incorporation counts per minute and thus reduced proliferation compared to WT CD4+ T cells 
(Figure 6A). This reduced responsiveness was confined to CD4+ T cells, as transgenic CD8+ T 
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cells showed no change in proliferation after stimulation with CD3 antibody (Figure 6B, middle 
panel). Normal reactivity of Clec16a KD CD4+ T cells was restored by circumventing TCR 
signalling via mitogen-mediated activation (data not shown), indicating that Clec16a KD 
reduces T cell responsiveness by affecting TCR signalling [106]. Notably, regulatory effector T 
cells (Tregs) in Clec16a KD mice showed no difference in suppressive function compared to 
WT Tregs (Figure 6B, right panel).  
 
 
Figure 15  * CD4+ T cells show reduced proliferation rates and are hyporeactive in Clec16a knockdown 
animals, as published by Schuster et al.  
Thymidine incorporation assay using 3H-thymidine, which is incorporated into new strands of DNA during mitotic 
cell division of T cells and can be measured as radioactive activity in counts per minute. (A) Reduced proliferation 
of Clec16a KD CD4+ T cells after stimulation with anti-CD3 (left panel) and CD3/CD28 covered beads (right panel).  
(B) Proliferation panels of CD4+ and CD8+ T cells of WT and Clec16a KD animals stimulated by anti-CD3 (left, 
middle panel), with reduced proliferation rates of Clec16a KD CD4+ T cells and unchanged proliferation rates of 
Clec16a KD CD8+ T cells. Suppression of WT CD4+ T cells by WT and Clec16a KD Tregs, with no change in 
suppressive function (right panel) [106].  
 
3.1.4. * The effects of Clec16a knockdown are not T cell intrinsic  
Previous results had suggested that autoimmune protection was mediated by hyporeactive T 
cells. Thus, further experiments were required to see whether these effects were caused by 
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gene KD and intrinsic changes within the cells. Due to the natural variegation of transgenesis 
after lentiviral infection, not every T cell expressed the transgene which included the reporter 
protein GFP. About 75% of all T cells in Clec16a KD mice were GFP+ and therefore expected to 
express the transgene. To further characterize the behavior of transgenic T cells, both GFP+ 
and GFP- cells were stimulated with anti-CD3 by Schuster et al. . Strikingly, both 
subpopulations showed similarly reduced proliferation response, independent on their 
transgene expression (Figure 7A). As hyporesponsiveness was independent on transgene 
expression in T cells, the effects of Clec16a KD had to be conveyed by another tissue. To test 
if the effect of Clec16a KD on T cells was mediated by hematopoietic cells, bone marrow (BM) 
chimeras were generated by Schuster et al. (see Chapter 2.3.4.2). Transgenic T cells that 
developed in contact with WT TECs showed a similar reactivity as WT T cells in the same 
environment (Figure 7B). Notably, irradiated WT NOD animals were not protected from 
diabetes, regardless of whether they had been reconstituted with WT or Clec16a KD BM 
(Figure 7C). In contrast, irradiated Clec16a KD mice reconstituted with WT BM or Clec16a KD 
BM remained protected from diabetes over more than 40 days (Figure 7D), suggesting that 
disease protection was not owed to gene KD in hematopoietic cells but perhaps another tissue 
of the knockdown animal.    
 
 
Figure 16  * The effects of Clec16a knockdown are not conveyed by changes in T cells or 
hematopoietic cells, as published by Schuster et al.  
(A) Thymidine incorporation assay using 3H-thymidine. Reduced proliferation of GFP+ and GFP- Clec16a KD CD4+ 
T cells after stimulation with anti-CD3, compared with WT CD4+ T cells. (B) Proliferation of CD4+ T cells in a WT 
BM chimeric mouse reconstituted with WT or Clec16a KD BM, stimulated by CD3/CD28 beads. (C) Diabetes 
frequency study. Rate of diabetes in WT BM chimeric mice reconstituted with WT or Clec16a KD BM. (D) Rate of 
diabetes in Clec16a KD BM chimeric mice reconstituted with WT or Clec16a KD BM, with disease protection of 
80% of all animals [106].  
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3.1.5. The effects of Clec16a knockdown are thymus intrinsic 
As part of this thesis, to test if the effects of Clec16a KD on T cells were perhaps conveyed by 
thymic epithelial cells during T cell selection, a thymic transplantation experiment was 
performed. For this, thymectomized and irradiated WT NOD animals were reconstituted with 
WT BM and subsequently transplanted with fetal thymi of either WT or Clec16a KD NOD 
embryos under the kidney capsule (see Chapter 2.3.4, and Figure 17). All animals survived 
anaesthesia and surgery with no follow-up mortality. After transplantation, a diabetes 
frequency study was conducted (see Chapter 2.3.4.5) to see which animals suffered from 
autoimmune diabetes.  
 
 
Figure 17  Thymic transplantation, schematic overview 
Thymectomized NOD WT mice of 4 weeks of age were purchased from Jackson Laboratory. Subsequently, mice 
were irradiated and reconstituted with NOD WT lineage-cell depleted bone marrow. 2 weeks later, thymic 
transplantation was performed and E14 lobes were transplanted under the kidney capsule. 6 weeks later 
cyclophosphamide was injected to accelerate onset of diabetes. Thrice per week mice were tested for glycosuria.  
 
Once completed, all animals were euthanized and dissected to study the success rate of 
thymic transplantation. All transplanted thymi had successfully grown underneath the kidney 
capsule (Figure 18). There was no organ rejection. At the time of dissection, all transplanted 
organs were well perfused and vital (Figure 18, left panel). Transplanted thymi did not show 
any macroscopic changes between the three test groups. The bottom right panel of Figure 18 
shows representative examples of fully functional, successfully transplanted thymi in all three 
experimental groups. Additionally, there was no difference in T cell composition post 
transplantation at the time of diabetes onset (data not shown) [106].  
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Figure 18  Transplantation of fetal thymi of WT or Clec16a knockdown NOD embryos 
A dissected WT NOD mouse after thymectomy, irradiation and successful transplantation of WT BM and fetal 
thymus, after the concluded diabetes study. (Enlarged): Example of a fetal thymus transplant (indicated by the 
blue line) underneath the kidney capsule, adhesive to the left kidney, vital, well perfused, with no difference in 
macroscopic appearance. (Right bottom panel): Examples of successfully transplanted fetal thymi in all three 
experimental groups.  
 
As expected, all WT NOD mice transplanted with WT BM and WT thymi developed 
autoimmune diabetes within 20 days. Most strikingly, WT NOD mice transplanted with WT 
BM, but Clec16a KD thymi, showed protection from autoimmune diabetes up to 40 days 
(Figure 19). Most notably, these findings suggested the effects of Clec16a KD were facilitated 
by changes within the thymus and perhaps a modified T cell selection.  
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Figure 19  * Disease protection is conveyed by changes in the thymic epithelium, as published by 
Schuster et al.  
Development of autoimmune diabetes in WT NOD mice, which were previously thymectomized at 4 weeks of 
age, irradiated and reconstituted with WT BM and subsequently transplanted with WT (n = 7) or Clec16a KD (K3 
n = 10, K5 n = 10) fetal thymi (E14). WT vs. KD, pooled data, p < 0.05, Log-rank test [106].  
 
3.1.6. Clec16a knockdown does not impair blood glucose homeostasis in NOD mice 
It had previously been reported that islet-specific deletion of Clec16a in the pancreas led to a 
decrease in insulin secretion of pancreatic  cells and a reduction of blood glucose tolerance 
in mice, suggesting that perhaps a reduction of insulin as auto-antigen was contributing to 
disease protection [123]. To test whether impaired insulin secretion was contributing to 
disease protection in the Clec16a KD NOD mouse, pancreatic islets were isolated from WT and 
Clec16a KD NOD mice and analyzed as part of this thesis. As shown in Figure 20, there was a 
significantly reduced expression level of Clec16a mRNA in KD animals relative to WT, indicating 
an effective gene KD in pancreatic islets.  
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Figure 20  Clec16a knockdown is effective in pancreatic islets of Clec16a knockdown NOD mice 
Relative expression of Clec16a mRNA in relation to -Actin in pancreatic islets of K5 Clec16a KD NOD mice (n = 
6) vs. WT animals (n = 6), data also representative of K3 animals (n = 6; data not shown), * p < 0.05, two-tailed t-
test.  
 
Insulin secretion and insulin content remained unchanged in pancreatic islets of Clec16a KD 
animals compared to WT mice (data not shown) [106]. Additionally, WT and Clec16a KD NOD 
mice were challenged by an intraperitoneal glucose tolerance test (IPGTT). Fasting blood 
glucose levels after overnight fast were comparable between WT and Clec16a KD animals as 
seen in Figure 21. Both groups showed physiological fasting blood glucose levels at t = 0 min. 
After glucose injection, there was an immediate and expected jump in blood glucose levels. 
Over time, WT and Clec16a KD animals showed no difference in blood glucose clearance with 
a similar blood sugar metabolism (Figure 21). These results highlight physiological blood 
glucose homeostasis in Clec16a KD animals with no direct effect on autoimmune diabetes, 
leaving the thymus as the pivotal organ involved in pathogenesis.   
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Figure 21  Blood glucose homeostasis remains unchanged in Clec16a knockdown animals 
Intraperitoneal glucose tolerance test. Total blood glucose levels over time after intraperitoneal challenge with 
glucose in WT and Clec16a KD (K3 and K5) NOD mice. Physiological fasting blood glucose levels after overnight 
fast in all groups at t = 0 min. Initial jump in blood glucose levels after immediate challenge with glucose, with no 
difference in blood glucose clearance between WT and KD animals.  
 
3.1.7. Clec16a and Dexi show similar expression patterns in the NOD mouse 
Although CLEC16A contains most autoimmune disease associated SNPs in the 16p13 region, 
recent studies have also started to focus on its neighboring genes such as SOCS1, CIITA and 
DEXI (see Chapter 1.5.2). It was reported that intron 19 of CLEC16A may act as a regulatory 
sequence for its neighbor DEXI, as the intron interacts with the promoter region of DEXI and 
is located in close proximity to the gene [90]. Additionally, other studies could demonstrate 
that CLEC16A serves as an expression quantitative trait locus (eQTL) for itself in pancreatic  
cells, for DEXI in monocytes and for DEXI and SOCS1 in thymic tissue [124]. Based on these 
findings, the effects of Clec16a KD in the NOD mouse were investigated in regard to gene 
expression levels of the 16p13 gene cluster.    
 
First, WT and Clec16a KD NOD mice were used to test detectability of all relevant 16p13 genes 
and to create an overview of gene expression levels in different tissues. Figure 22 serves as an 
example of first preliminary data collected in different murine tissues, presenting expression 
levels of the 16p13 gene cluster in kidney and liver produced with qPCR. As expected, CIIta 
shows only little expression in kidney and liver, as it is mostly expressed in tissues which 
harbor MHC class II carrying APCs [125]. Socs1, Clec16a and Dexi show expression levels similar 
to those previously reported in liver and kidney in various databases. Most notably, it appears 
as if Clec16a and Dexi show similar expression patterns independent of genotype.  
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Figure 22  Relative expression of the 16p13 gene cluster in WT and Clec16a knockdown NOD mice 
qPCR of liver and kidney samples from the NOD mouse. Expression of CIIta, Dexi, Clec16a and Socs1 relative to 
-Actin in WT (n = 3) and Clec16a KD (K3 n = 3, K5 n = 3) animals.  
 
As there is no established link between CLEC16A risk SNPs and CIITA expression levels in 
literature, further experiments solely focused on Clec16a, Dexi and Socs1. WT NOD mice were 
used to establish a gene expression profile for these genes using qPCR. Among others, the 
cerebellum, liver and kidney have been reported to show relatively high expression levels of 
Clec16a, which is why these tissues were used as a reference point [84]. Additionally, due to 
the immunological nature of T1D, these experiments focused on lymphoid tissues such as 
thymus, spleen and lymph nodes, as well as the pancreas.  
 
Matching the results reported in human, Socs1 in the NOD mouse is mainly expressed in 
lymphoid tissue, especially the thymus and lymph nodes (Figure 23A) [126]. Clec16a and Dexi 
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mRNA expression in the NOD mouse is relatively high in brain, kidney and liver, which is also 
consistent with human data (Figure 23A) [127, 128]. While there is a clear difference in 
expression levels compared to Socs1, both Clec16a and Dexi show a distinctly similar gene 
expression pattern in almost all tested tissues (Figure 23B).    
 
 
Figure 23  Clec16a and Dexi share a gene expression pattern in the WT NOD mouse 
(A) Expression of Clec16a, Dexi and Socs1 mRNA relative to -Actin expression in WT NOD mice (n = 6) in thymus, 
spleen, pancreatic lymph node, liver, kidney and brain via qPCR. (B) Same data set as in (A), direct comparison of 
Clec16a and Dexi expression levels. No difference in expression patterns, except for a significantly increased 
expression of Dexi in the brain, * p < 0.05, two-tailed t-test.  
 
3.1.8. Clec16a, Dexi and Socs1 expression levels are reduced in Clec16a knockdown mice 
As previously reported, CLEC16A and CLEC16A variations act as potential eQTLs for DEXI and 
SOCS1 in the thymus [91, 124]. To test whether similar results could be found in the Clec16a 
KD NOD mouse, thymic tissue samples were analysed as part of this project. Real-time qPCR 
confirmed an effective gene KD with significantly decreased expression levels of Clec16a in 
the thymus (Figure 24). Additionally, with the successful Clec16a KD, there is a distinct 
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decrease in Dexi and Socs1 gene expression, with a clear trend for Dexi (p = 0.054) and similar 
results for Socs1 (Figure 24).  
 
 
Figure 24  Clec16a knockdown in the NOD mouse is accompanied by a decrease in Dexi and Socs1 
expression in the thymus 
Expression of Clec16a, Dexi and Socs1 relative to -Actin expression in thymic tissue of Clec16a KD NOD mice (n 
= 3 per group) via qPCR. Effective gene KD of Clec16a, * p < 0.05, two-tailed t-test.  90% reduction of Dexi 
expression in the Clec16a KD animals, p = 0.054, two-tailed t-test. 60% reduction of Socs1 expression in the 
Clec16a KD mouse, p = 0.076, two-tailed t-test.  
 
With regard to the pathogenesis of autoimmune diabetes, the previous experiment was also 
conducted in pancreatic islets. Interestingly, identical results were obtained for the expression 
patterns of Clec16a, Dexi and Socs1 in the pancreas of NOD mice. As there is a statistically 
significant gene KD of Clec16a in pancreatic islets, Dexi and Socs1 show a clear trend of 
reduced gene expression (Figure 25). Taken together, these results (Figure 24, Figure 25) 
suggest a possible regulatory role for Clec16a as an eQTL for Dexi and Socs1 in the NOD mouse 
model. 
Results 
 62 
 
Figure 25  Clec16a knockdown in the NOD mouse leads to reduced gene expression of Dexi and Socs1 
in pancreatic islets 
Expression of Clec16a, Dexi and Socs1 relative to -Actin expression in isolated pancreatic islets of Clec16a KD 
NOD mice (n = 3 per group) via qPCR. Effective gene KD of Clec16a, * p < 0.05, two-tailed t-test. Reduced relative 
expression of Dexi and Socs1 in the Clec16a KD animals.   
 
3.2. In vitro results 
Based on the previously discussed in vivo results, it was hypothesized that the effects of 
Clec16a KD on T cell selection and T cell responsiveness were conveyed by changes in thymic 
epithelial cells. As previously reported and explained in Chapter 1, the drosophila ortholog of 
CLEC16A ema is implicated in autophagy. Autophagy, in turn, is required in thymic epithelium 
for antigen presentation and T cell selection. The following in vitro experiments were 
conducted to study the function of Clec16a in autophagy and to investigate a possible link 
between autophagy and T cell selection.   
 
3.2.1. * Clec16a silencing impairs autophagy in thymic epithelial cells   
Thymic epithelium is essential for T cell selection and the generation of a healthy T cell 
repertoire. As described in Chapter 1.4.3., TECs have been shown to use autophagy as a 
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pathway to load antigen into the MHC class II pathway. Here, Schuster et al. had investigated 
the effects of Clec16a KD on autophagy in thymic epithelial cells. For this, MJC1 cells were 
used, which had been derived from murine cortical thymic epithelium (see Chapter 2). 
Schuster et al. created Clec16a KD MJC1 cells, which showed effective gene KD (Figure 26A). 
Additionally, as a positive control for impaired autophagy, the autophagy-related gene Atg5 
was silenced in these cells. To investigate autophagy in TECs, the autophagy markers LC3 and 
p62 were quantified in Clec16a KD and Atg5 KD MJC1 cells. Strikingly, Clec16a KD resulted in 
a reduced LC3-II/LC3-I ratio and accumulation of p62 in TECs, similar to Atg5 KD, indicating 
impaired autophagy (Figure 26B) [106].  
 
 
Figure 26  * Clec16a knockdown in MJC1 cells results in impaired autophagic degradation and flux, as 
published by Schuster et al.  
(A)  Relative expression of Clec16a mRNA in MJC1 cells in qPCR, significantly reduced with ** p < 0.01, two-tailed 
t-test (left panel). Protein expression levels via Western blot, significantly reduced with * p < 0.05 two-tailed t-
test (middle and right panel). (B) Quantification of LC3-I, LC3-II and p62 via Western blot in control, Clec16a KD 
and Atg5 KD MJC1 cells. Cells were starved and treated with autophagy inhibitor E64d to measure LC3 (left 
panel). For quantification of p62, cells were treated with autophagy inducer rapamycin (R) or autophagy inhibitor 
3-methyladenine (M), or cells were without treatment (-) (right panels) [106].  
 
3.2.2. CLEC16A knockdown alters autophagy in human cells 
Based on these findings, the function of CLEC16A was tested in human cells as part of this 
thesis to see if its role in autophagy was evolutionarily preserved in human. For this, CLEC16A 
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KD HeLa cells were generated (see Chapter 2.1.3.). CLEC16A knockdown was induced in HeLa 
cells via lentiviral transgenesis to create two transgenic cell lines (K3 and K5). As a positive 
control, ATG5 KD HeLa cells were generated as a reference for impaired autophagy. Figure 27 
shows the effective gene knockdown of both ATG5 and CLEC16A in HeLa cells (K3), with 
similarly effective results for the K5 cell line (data not shown).   
 
Figure 27  Effective knockdown of ATG5 and CLEC16A in HeLa cells 
qPCR of HeLa cells. Expression levels of ATG5 mRNA in the ATG5 KD HeLa cell line with a statistically significant 
reduction of expression, ** p < 0.01, two-tailed t-test (left panel). Relative expression levels of CLEC16A mRNA 
in the K3 KD HeLa cell line, with a statistically significant reduction of expression, * p < 0.05, two-tailed t-test 
(right panel). Data of K3 KD HeLa cells is representative of K5 KD HeLa cells.  
 
To study the effect of CLEC16A KD on autophagy, p62 degradation was quantified via Western 
blot in CTRL, CLEC16A KD and ATG5 KD HeLa cells. CTRL cells were transduced with shRNA 
targeting a luciferase not present in HeLa cells and served as a negative control. ATG5 KD cells 
served as a positive control. All cells were starved over 24h to ensure induced autophagy. 
Remarkably, there was significantly more p62 accumulation in CLEC16A KD cells, with similar 
results in ATG5 KD cells (Figure 28). As p62 is normally degraded under starved conditions by 
a functioning autophagy, the accumulation of p62 in CLEC16A KD HeLa cells is implicative of 
impaired autophagy. After treatment with autophagy inhibitors, similar results were observed 
with increased levels of p62, but no statistical significance (data not shown).  These results are 
representative of three individual experiments.  
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Figure 28  Accumulation of p62 in starved CLEC16A and ATG5 knockdown HeLa cells 
Western blot showing protein levels of the autophagy marker p62 in CTRL, CLEC16A KD and ATG5 KD HeLa cells, 
under starved conditions (left panel), with ACTIN as loading control. Protein expression levels of p62 in CTRL, 
CLEC16A KD und ATG5 KD HeLa cells after quantification relative to ACTIN levels (right panel), statistical 
significance ** p < 0.01, two-tailed t-test. Data is representative of three experiments.  
 
To further investigate autophagy in CLEC16A KD HeLa cells, LC3 levels were measured as a 
marker for autophagic flux (see Chapter 1.4.4.1) in CTRL, ATG5 KD and CLEC16A KD HeLa cells. 
After overnight starvation and treatment with the autophagy inhibitor E64d, autophagic flux 
was intact in CTRL HeLa cells as there was normal turnover of LC3-I to LC3-II, and LC3-II 
accumulated due to treatment with E64d (Figure 29). Remarkably, autophagic flux appeared 
to be impaired in CLEC16A KD HeLa cells with similar results in ATG5 KD HeLa cells, as there 
was a significant reduction in LC3-II/LC3-I ratio with no apparent accumulation of LC3-II 
relative to LC3-I (Figure 29, top panel). In a second control, treatment with a different 
autophagy inhibitor called Pepstatin A resulted in similar results (Figure 29, bottom panel). In 
CTRL HeLa cells, LC3-I was converted to LC3-II, but LC3-II was not further degraded due to 
inhibition through Pepstatin A, resulting in a relatively high LC3-II/LC3-I ratio. In comparison, 
in CLEC16A KD and ATG5 KD HeLa cells, there was less turnover of LC3-I to LC3-II, which 
resulted in reduced LC3-II/LC3-I ratios, indicating impaired autophagy. Taken together, there 
is no increase in LC3-II in starved CLEC16A KD HeLa cells after treatment with protease 
inhibitors, similar to the results in ATG5 KD cells, which demonstrates reduced autophagic flux 
and confirms impaired autophagy. Based on these findings there is a clear role of CLEC16A in 
autophagy in human. 
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Figure 29  Reduced LC3-II / LC3-I ratios in CLEC16A and ATG5 knockdown HeLa cells 
Western Blot of LC3-I and LC3-II as a marker of autophagic flux in CTRL, CLEC16A KD and ATG5 KD HeLa cells, 
under starved conditions. After treatment with autophagy inhibitor E64d (top panel) or Pepstatin A (bottom 
panel), there is less turnover of LC3-I to LC3-II in CLEC16A KD and ATG5 KD HeLa cells, with a significantly reduced 
LC3-II/LC3-I ratio, ** p < 0.01, two-tailed t-test.  
 
3.2.3. * Clec16a knockdown modifies thymocyte stimulation by MJC1 cells due to  
impaired autophagy  
Finally, it was examined by Schuster et al. if there was a direct link between TEC autophagy 
and altered T cell selection owed to Clec16a KD. For this, Schuster et al. co-cultured the 
previously generated MJC1 cells with CD69lo DP thymocytes and found that the majority of 
immature thymocytes developed regularly into SP CD4 cells with an upregulation of the early 
activation marker CD69. However, when co-cultured with Clec16a KD MJC1 cells, developing 
thymocytes showed impaired upregulation of CD69 and reduced proliferation [106, 129].  
 
In the scope of this thesis, to test if there is a direct link between impaired TEC autophagy and 
reduced T cell activation, MJC1 cells were transduced with an LC3 transgene that also encoded 
for OVA323-339, a peptide tied to LC3 and to the autophagy-dependent antigen loading process 
of MHC class II molecules [130]. Thymocytes with a specific TCR for OVA323-339, so called OT-II 
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thymocytes [131], were co-cultured with MJC1 cells expressing the OVA323-339-LC3 construct. 
OT-II thymocytes stimulated by Ctrl MJC1 cells showed regular proliferation, while OT-II 
thymocytes stimulated by Clec16a KD and Atg5 KD MJC1 cells demonstrated reduced 
activation (Figure 30). This indicated that Clec16a KD (similar to Atg5 KD) modulated 
autophagy-dependent antigen presentation and reduced T cell stimulation. Hereafter, a 
mutation of the OVA323-339-LC3 construct (LC3G120A) cleavage site was introduced as part of this 
thesis, which prevented the peptide from being integrated into autophagosomes and the 
autophagy-dependent antigen presentation pathway. Finally, OT-II thymocytes stimulated by 
Ctrl MJC1 cells carrying the mutated construct displayed the same reduced proliferation 
pattern as seen after stimulation by Clec16a KD MJC1 cells without the mutated construct 
(Figure 30). This suggested that inhibition of autophagy-dependent antigen presentation via 
the mutated OVA323-339-LC3 construct mirrored the effects of Clec16a KD. In summary, these 
results reveal a role of Clec16a in autophagy-related stimulation of thymocytes by TEC.    
 
Figure 30  * Clec16a knockdown affects T cell stimulation by MJC1 cells, as published by Schuster et al. 
Percentage of TCRhi OT-II thymocytes after stimulation of immature OT-II thymocytes by Crtl, Clec16a KD or Atg5 
KD TECs. TECs had been transduced with OVA323-339-LC3 constructs (black) or OVA323-339-LC3mut constructs (white), 
respectively. Reduced thymocyte proliferation after stimulation with Clec16a KD and Atg5 KD MJC1 cells 
compared to WT MJC1 cells (black bars). Significant decrease in thymocyte proliferation after stimulation with 
WT MJC1 cells carrying the LC3G120A mutation, mirroring the effects of Clec16a KD and Atg5 KD (white bars). * p 
< 0.05, two-tailed t-test [106].  
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4. Discussion 
4.1. Clec16a knockdown protects the NOD mouse from autoimmune 
diabetes 
The NOD mouse is a common experimental model for the development and study of 
autoimmune diabetes [110]. Strikingly, knockdown of Clec16a protected almost all NOD mice 
from spontaneous diabetes (Results, Figure 11A). As the mechanisms of Clec16a KD remained 
unknown, and based on the autoimmune pathogenesis of T1D, this work investigated whether 
Clec16a KD affected autophagy in TECs, T cell selection and the immune system to convey 
disease protection.  As seen in Figure 11, the transfer of Clec16a KD splenocytes protected 
from diabetes, while animals injected with WT splenocytes developed disease. This protective 
role of transgenic splenocytes indicates that disease protection is indeed conveyed by changes 
within the immune system. Further experiments demonstrated disease protection was 
mediated by transgenic T cells and independent of the genotype of B cells (Results, Figure 
11D). Markedly, these results are in line with the widely accepted theory that T1D is a mostly 
T cell mediated autoimmune disease [132], and suggest a critical protective role of T cells in 
Clec16a KD NOD mice.  
 
To further distinguish which specific immune cells were affected by Clec16a KD, T cell 
subpopulations were stimulated via TCR signaling and proliferation was measured. 
Interestingly, CD4+ T cells of Clec16a KD animals were hyporeactive after TCR stimulation, 
while CD8+ T cells of Clec16a KD animals showed normal proliferation (Results, Figure 15). 
Although cytotoxic CD8+ T cells are regarded as the effectors of pancreatic  cell destruction 
[133] and constitute the majority cell population within insulitis lesions [19], CD4+ T cells are 
of critical importance in the pathogenesis of T1D and immune tolerance. They stimulate B cells 
to produce (auto-)antibodies, stimulate effector CD8+ T cells to destroy pancreatic  cells, and 
they release cytokines to induce macrophages [134]. Hence, hyporeactivity of CD4+ T cells in 
Clec16a KD animals could be the underlying mechanism of disease protection. Markedly, CD4+ 
T regulatory cells were not affected by Clec16a KD and displayed regular proliferation after 
TCR stimulation (Results, Figure 15B, right panel). This could be explained by their innately 
reduced dependency on TCR signaling [135].  
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Knowing that T cells were hyporeactive in Clec16a KD animals, pancreatic tissue of these 
animals was analyzed to see if there was a subsequent change in pancreatic inflammation. 
Strikingly, insulitis scoring showed that Clec16a KD reduced the severity of pancreatic 
inflammation and lymphocytic infiltration in the NOD mouse (Results, Figures 13 and 14). 
Nonetheless, all stages of insulitis were found in both WT and Clec16a KD groups, including 
‘no insulitis’. Notably, there was an increase in severity of insulitis in WT NOD animals with 
older age. In contrast, while Clec16a KD animals also suffered from insulitis, the rate and 
severity of it were drastically reduced compared to WT mice of the same age (Results, Figure 
14). Within the scope of this thesis, the investigator could not be blinded for this large 
experiment. To increase the power of this experiment and to compensate for a potential bias, 
more than 3500 individual islets were analyzed manually, and insulitis scoring was performed 
as reported and validated in literature [120]. Previous reports from human data have 
identified insulitis as a characteristic lesion in young T1D patients. Although it can be 
completely absent in T1D patients, it is regarded as a pathognomonic lesion [136]. Taken 
together, the results mentioned above match previous findings and serve as a potential 
histopathological explanation of disease protection in Clec16a KD mice. To increase the 
validity of this particular experiment, the analysis could be replicated with a blinded 
investigator in further studies.  
 
4.2. The effects of Clec16a knockdown are thymus-intrinsic 
Expression of lentiviral transgenes can vary depending on the integration site of the transgene, 
but this variegation can be improved greatly by using a superior lentiviral construct  [94]. In 
Clec16a KD animals, approximately 75% of T lymphocytes expressed the transgene which 
included a GFP reporter protein. Strikingly, T cells in Clec16a KD animals were hyporeactive 
independent on whether they expressed the transgene (GFP+) or not (GFP-) (Results, Figure 
16A). This suggests that T cells are not hyporeactive because of internal changes caused by 
Clec16a KD within the cell, but perhaps because of changes in other cell populations or tissues 
interacting with T cells. Following up on that, Schuster et al. could show that disease 
protection was surprisingly not conveyed by hematopoietic cells as WT NOD mice suffered 
from diabetes, regardless of whether they had been reconstituted with WT or Clec16a KD 
bone marrow (Results, Figure 16C). In contrast, the work for this thesis found almost all 
Clec16a KD animals protected from diabetes, no matter the genotype of the transplanted 
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bone marrow (Results, Figure 16D). This clearly indicates that disease protection is not 
conveyed by hematopoietic cells, but by changes in another tissue.  
 
One study had reported that Clec16a KD affected pancreatic  cells and reduced insulin 
secretion [123]. To test whether T cells in Clec16a KD animals were hyporeactive because of 
changes in the pancreas and due to a lack of the insulin antigen, intraperitoneal glucose 
tolerance tests were performed. Notably, there was no difference in insulin secretion, and 
blood glucose metabolism in Clec16a KD animals was similar to WT animals (Results, Figure 
21). As a next step, it would be interesting to repeat the experiment in animals with a 
complete gene knockout. Nevertheless, changes in insulin secretion or glucose metabolism 
could not be found in Clec16a KD mice used for this work and, therefore, cannot be 
accountable for disease protection in NOD mice.   
 
Based on the autoimmune nature of T1D, the lymphatic tissue is known to play a vital part in 
disease pathogenesis. Namely, the thymus is known as the essential location for T cell 
maturation and selection [137, 138]. More specifically, in recent years it has become clear that 
interactions between thymic epithelial cells and self-peptide:MHC complexes are critical to 
positive and negative selection of developing thymocytes [42]. To test if T cell hyporeactivity 
in Clec16a KD animals was caused by changes within the thymus, a thymic transplantation 
experiment was performed on thymectomized, irradiated WT NOD mice, which had been 
reconstituted with lineage depleted WT bone marrow. Most strikingly, transplantation of 
Clec16a KD fetal thymus protected WT NOD mice from spontaneous diabetes, whereas 
transplantation of WT fetal thymus did not protect from disease (Results, Figure 19). This 
suggests firmly that disease protection derives from Clec16a KD in the thymus. Subsequent 
elaboration on this by Schuster et al. could show that indeed T cell selection was impaired in 
Clec16a KD animals, specifically the transition from DP to CD4 SP T cells [106].  
 
4.3. Clec16a serves as a potential expression quantitative trait locus for its 
neighboring genes 
GWAS have identified many susceptibility SNPs located on the chromosome 16p13 locus 
encompassing CLEC16A, DEXI, SOCS1 and CIITA. These variants are in strong linkage 
disequilibrium. Some recent studies have reported that CLEC16A can act as a quantitative 
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expression trait locus for its neighboring genes such as DEXI and SOCS1 in MS patients [90, 91, 
124]. To this day, it remains quite difficult to understand each individual functional and causal 
contribution to disease pathogenesis. To see if there was any correlation between Clec16a 
and its neighboring genes under knockdown conditions in the NOD mouse, Clec16a KD tissues 
and cells were analyzed and gene expression levels were compared. The data shown in Figure 
22 represents preliminary data in exemplary organs, and has to be interpreted with caution, 
as there is no clear gene KD detectable. Further refinement of these experiments resulted in 
more viable data, as seen in Figures 23-25. Most notably, in various tissues of WT NOD mice, 
Clec16a and Dexi show distinct similarity of mRNA expression levels (Results, Figure 23).  With 
a focus on T1D, tissues such as the thymus and pancreatic islets were further analyzed. 
Interestingly, with Clec16a KD comes a remarkable reduction of Dexi and Socs1 mRNA 
expression levels, both in the thymus and in the pancreas (Results, Figures 24, 25). As these 
preliminary qPCR results imply, there may be a direct correlation of expression levels of 
Clec16a, Dexi and Socs1 in Clec16a KD animals. This, in turn, could mean that Clec16a indeed 
serves as an eQTL in the NOD mouse or perhaps serves a regulatory purpose for its 
neighboring genes. Obviously, these studies would need to be vastly expanded upon to better 
understand the functions and mechanisms of said genes. This, however, was not feasible 
within the scope and time limitations of this thesis. Nonetheless, the preliminary data 
acquired by this work was used to initiate further studies to characterize the neighboring gene 
Dexi by colleagues at the Kissler lab (unpublished data).    
 
4.4. The role of Clec16a in autophagy is conserved in human cells 
The preceding results from Schuster et al. and the experiments conducted for this thesis 
demonstrate that the effects of Clec16a KD originate from within the thymus and impair T cell 
selection. T cell selection is highly dependent on a functional thymic epithelium [42], which 
led to the assumption that perhaps Clec16a KD affected thymic epithelial cells and thereby 
altered T cell selection. Remarkably, recent studies discovered that Clec16a and its orthologs 
play a vital role in drosophila and mice autophagy [58, 106, 123, 139]. Additionally, autophagy 
has been identified as a prominent feature in TEC as a major contributor of peptide to the 
MHC class II loading process [46, 47, 62]. Building on the most recent finding that Clec16a KD 
indeed impaired autophagy in TEC of NOD mice [106], this study aimed to investigate a 
possible link between CLEC16A KD and impaired autophagy in human cells. To adequately 
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study the autophagic process in human cells, accumulation of p62 and the conversion of LC3-
I to LC3-II were measured in HeLa cells via Western blot [63, 69].  
 
To test autophagy in HeLa cells, at first, gene knockdowns of CLEC16A and ATG5 were 
generated and confirmed via qPCR (Results, Figure 27), using ATG5 as a positive control. Due 
to the lack of a reliable and thoroughly tested antibody for CLEC16A at the time, this work 
refrained from measuring protein levels via Western blot and relied on mRNA expression 
levels to detect knockdown, as is customary in experimental design after siRNA induced mRNA 
silencing [140]. To test the validity of p62 and LC3 as autophagy markers, HeLa cells were 
starved for autophagy induction, and protein levels were measured. HeLa cells carrying a 
control plasmid showed reduced levels of p62 (Results, Figure 28), which was interpreted as 
a sign of regular p62 clearance and intact autophagy [69]. Considering the difficulties of 
interpreting LC3 levels without the use of protease inhibitors, data of starved HeLa cells 
without treatment of protease inhibitors was not analyzed any further. Control HeLa cells 
treated with protease inhibitors, however, showed an increase in LC3-II/LC3-I ratio, which can 
be interpreted as a regular conversion of LC3-I to LC3-II with no further degradation of LC3-II 
owed to protease inhibitor treatment. As these findings were reproducible and consistent 
with literature, p62 and LC3 were confirmed as autophagy markers in HeLa cells.  
 
Under starved conditions, p62 degradation was significantly reduced in CLEC16A KD HeLa cells 
compared to control cells, with equal results for ATG5 KD (Results, Figure 28). Naturally, under 
starved conditions and induced autophagy, control cells would show an increased clearance 
of p62. Accumulation of p62 in CLEC16A KD cells suggests a dysfunctional autophagic process. 
To further increase a potential effect of CLEC16A KD on autophagy, protease inhibitors were 
added to these experiments. Unfortunately, results of treatment with protease inhibitors 
showed too much variance, which is why that data was not analyzed further. Optimally, the 
immunoblot for p62 could be repeated under starved conditions and with treatment of 
protease inhibitors. Considering that the first results were already of statistical significance, 
there was no scientific need to repeat these experiments with protease inhibitor treatmet in 
regard to the strict time limitations of this experimental work.  
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LC3 conversion rates were studied under starved conditions and treatment with protease 
inhibitors such as E64d and Pepstatin A. Bafilomycin A1 was also used as a protease inhibitor 
but did not yield any valid data. In WT cells, after treatment with protease inhibitors, LC3-II 
accumulates due to inhibition of LC3-II degradation, and the LC3-II/LC3-I ratio increases as 
LC3-I is converted to LC3-II. Strikingly, in CLEC16A KD cells, as well as ATG5 KD cells, LC3-II/LC3-
I ratios were significantly reduced compared with control cells (Results, Figure 29). This shows 
a reduced conversion of LC3-I to LC3-II and confirms impaired autophagic flux in CLEC16A KD 
cells. Taking these results together, the previous discovery of impaired autophagy in Clec16a 
KD TECs [106] could be reproduced in human cells. This underlines that the function of Clec16a 
is conserved in human and that there is a clear link between CLEC16A, impaired autophagy 
and autoimmune disease.  
 
4.5. Clec16a knockdown alters autophagy in thymic epithelium and 
modulates T cell selection  
Analogous to the effects of CLEC16A KD in HeLa cells, knockdown of Clec16a results in 
impaired autophagy in thymic epithelial cells of the NOD mouse [106]. This led to the question 
if the effects of Clec16a KD on TEC autophagy were directly linked to thymocyte stimulation. 
To further investigate this, TEC derived MJC1 cells were used to stimulate immature 
thymocytes [106]. Beforehand, MJC1 cells were transduced with an LC3 construct containing 
the OVA323-339 peptide, which allowed for antigen presentation restricted only to autophagy-
dependent MHC class II loading [130]. Additionally, a mutated construct was introduced which 
prevented autophagy-dependent presentation of the OVA antigen. Stimulation by Clec16a KD 
and Atg5 KD MJC1 cells resulted in reduced proliferation of TCRhi OT-II cells (Results, Figure 
30). Strikingly, stimulation via control MJC1 cells carrying the mutated OVA323-339-LC3 
construct led to a similar reduction in proliferation (Results, Figure 30). This indicates that 
disruption (in this case via mutation) of the autophagy-dependent MHC class II loading process 
mirrors the effects of Clec16a KD and Atg5 KD in thymic epithelial cells. This, in turn, 
emphasizes the direct link between Clec16a KD, impaired autophagy and thymocyte 
stimulation.  
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4.6. CLEC16A and its role in autoimmune disease 
CLEC16A is associated with a variety of autoimmune diseases. This thesis demonstrates a 
crucial role for the gene in immune tolerance and regulation. Its effects on autophagy 
modulate antigen presentation in the thymus and lead to hyporeactive T cells and disease 
protection in the NOD mouse. Constitutive autophagy is a characteristic feature of TEC [141]. 
TEC autophagy is at least partially involved in generating the MHC class II ligandome [62, 142]. 
Additionally, it was shown that LC3 co-localizes with MHC class II loading proteins in epithelial 
cells [130], as well as that autophagy directly interacts with the MHC class II loading process 
in TECs [62]. It remains unanswered as to how exactly CLEC16A affects the selection and 
presentation of self-peptide in the thymus. However, there are a few possible explanations 
for this. First, the effects of CLEC16A KD could impair autophagy and antigen presentation in 
the thymic cortex and lead to reduced positive selection, which in turn would result in more 
‘death by neglect’ at the early stages of thymocyte development. Notably, in Clec16a KD 
animals, there was a distinct reduction in thymocytes undergoing selection (TCRint/hi CD69hi) 
and a relative over-expression of immature thymocytes (TCRlo CD69lo) [106]. As CD69+ is a 
marker for transitional cells between the DP and SP developmental stages, these findings 
would support the idea of reduced positive selection [129]. Secondly, the effects of CLEC16A 
KD could alter autophagy in the medullary thymic epithelium, which would modulate the 
presentation of tissue restricted antigen and perhaps, due to qualitative or quantitative 
changes of self-peptide, lead to increased negative selection. Indeed, members of the Kissler 
Lab could demonstrate an increase in negative selection after Clec16a KD by measuring the 
expression of Helios, a transcription factor that marks thymocytes undergoing deletion [106]. 
Third, it could be a combination of both, altered positive and negative selection, as well as 
additional effects conveyed by changes during the maturation process of thymocytes.  
 
In order to better understand the function of CLEC16A, more experiments have to be 
conducted, especially in regard to T cell selection, and the molecular mechanisms of the gene. 
Several studies have tried to characterize CLEC16A in more detail. One group speculated that 
human CLEC16A regulated autophagy through mTOR [143], while other groups postulated 
that Clec16a is regulated by Pdx1 and mediates mitophagy by regulation of an E3 ubiquitin 
ligase called Nrdp1 in pancreatic  cells [144], as other groups declared Clec16a as an 
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expression quantitative trait locus for its neighboring genes Dexi and Socs1 [91]. Clearly, 
further investigation of the gene is required to illuminate the function and role of CLEC16A.  
In this respect, as part of this thesis, confocal microscopy experiments were initiated to 
investigate potential co-localization of CLEC16A with other molecules involved in autophagy 
and antigen presentation, i.e. LC3, LAMP1 and HLA (date not shown). Furthermore, this 
project initiated a test to see if changes in autophagy were consistent with different human 
risk SNPs. For this, the first steps of a functioning CRISPR/Cas9 system were established at the 
Kissler Lab as ground work for future studies. Additionally, the neighboring gene Dexi will 
actively be investigated by members of the Kissler Lab, to further characterize this potential 
immunoregulatory gene and its association with Clec16a.  
 
In summary, this work confirms that the effects of Clec16a KD on autophagy are conserved in 
human, strengthening previous results of similar function in drosophila [58] and mice [106, 
123]. As the mechanistical function of CLEC16A remains elusive, the functional role of CLEC16A 
provides a better understanding of TEC autophagy, T cell selection and disease protection. 
Establishing a link between impaired autophagy, altered antigen presentation and 
autoimmunity, this thesis suggests a vital role for CLEC16A as a regulator of immune tolerance 
and autoimmune disease in human.   
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5. Summary 
Genome-wide association studies revealed CLEC16A as a candidate gene for Type 1 Diabetes 
and multiple other autoimmune disorders [72]. The function of CLEC16A remains unknown. 
However, previous work showed that the CLEC16A ortholog ema and the murine Clec16a were 
both implicated in autophagy, a process partially required for MHC class II loading and antigen 
presentation [58, 123]. Furthermore, studies could show that autophagy was required in 
thymic epithelial cells for antigen presentation during T cell selection, suggesting a possible 
role of CLEC16A in T cell selection in the thymus [46, 47]. Additionally, it was postulated that 
CLEC16A may function as an expression quantitative trait locus for its neighboring genes [91, 
124] and that Clec16a KD was involved in pancreatic islet function and impaired insulin 
secretion and glucose homeostasis [144]. Prior to this work, Schuster et al. had created a 
Clec16a KD NOD mouse, which was protected from spontaneous autoimmune diabetes [106].  
 
For this work it was hypothesized that CLEC16A variation serves as a Type 1 Diabetes risk gene 
by affecting autophagy in thymic epithelial cells, which modulates antigen presentation and 
shapes the T cell repertoire. To expand and complement previous findings by Schuster et al., 
this thesis aimed to investigate how CLEC16A modifies the function of thymic epithelial cells. 
For this purpose, CLEC16A KD was induced in human cells via RNA interference and autophagy 
was studied through immunoblotting. Additionally, inflammation of pancreatic tissue in 
Clec16a KD NOD mice was scored using H.E. stained pancreatic sections. Thymic 
transplantation experiments were conducted to test whether the effects of Clec16a KD were 
T cell intrinsic. Also, intraperitoneal glucose tolerance tests were performed to study glucose 
homeostasis in Clec16a KD NOD animals. Finally, using qPCR, gene expression levels of 
neighboring genes such as Dexi and Socs1 were measured to study Clec16a as an expression 
quantitative trait locus. 
 
In combination with the findings of Schuster et al., this thesis demonstrates that Clec16a KD 
reduces the severity of insulitis and protects from onset of spontaneous diabetes in the NOD 
mouse. Disease protection is conveyed by impaired autophagy in TEC, which leads to altered 
T cell selection and hyporeactive CD4+ T cells. The effects of Clec16a KD in the NOD mouse are 
thymus intrinsic. Glucose homeostasis remains unchanged in the Clec16a KD NOD mouse and 
plays no role in disease protection. Clec16a and Dexi presented similar expression levels, but 
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further studies are required to investigate a clear link between these two genes. Finally, 
impaired autophagy could be replicated in human CLEC16A KD cells, which demonstrates a 
conserved function of CLEC16A and suggests a possible link between CLEC16A variation and 
risk of autoimmune disease in human.  
 
6. Zusammenfassung 
Genomweite Assoziationsstudien haben CLEC16A als ein Suszeptibilitätsgen für Typ 1 Diabetes 
und weitere Autoimmunerkrankungen identifiziert [72]. Die genaue Funktion von CLEC16A 
bleibt jedoch ungeklärt. Studien zeigten, dass sowohl das Drosophila Ortholog ema als auch 
das murine Clec16a eine Rolle in Autophagie spielen. Autophagie trägt zur Beladung der MHC-
Klasse-II Moleküle und somit der Antigenpräsentation bei [58, 123]. Darüber hinaus konnten 
Studien belegen, dass Autophagie zur Antigenpräsentation während der T-Zell Selektion in 
Thymus-Epithelzellen benötigt wird [46, 47].  Dies schlägt eine mögliche Funktion von 
CLEC16A in Thymus-Epithelzellen während der T-Zell Selektion vor. Außerdem berichteten 
Arbeiten, dass CLEC16A als quantitativer Trait Locus für seine Nachbargene fungiert [91, 124] 
und dass Clec16a KD in Langerhans Inseln im Pankreas die Insulinsekretion und den 
Glukosestoffwechsel beeinträchtigt [144]. Dieser Arbeit vorausgehend hatten Schuster et al. 
eine Clec16a KD NOD Maus generiert, welche vor spontanem autoimmunem Diabetes 
geschützt war [106].  
 
Für diese Arbeit wurde vermutet, dass CLEC16A als Suszeptibilitätsgen für Typ 1 Diabetes den 
Prozess der Autophagie in Thymus-Epithelzellen beeinträchtigt und somit 
Antigenpräsentation und das T-Zell Repertoire beeinflusst. Um auf der Vorarbeit von Schuster 
et al. aufzubauen und diese zu ergänzen, zielte diese Arbeit darauf ab, den Einfluss von 
CLEC16A auf Thymus-Epithelzellen zu untersuchen. Hierfür wurde ein CLEC16A KD in 
menschlichen Zellen mittels RNA Interferenz erzeugt und Autophagie durch Immunoblotting 
untersucht. Zusätzlich wurde die Entzündung im Pankreasgewebe von Clec16a KD NOD 
Mäusen mittels H.E. Färbung beurteilt und bewertet. Thymus-Transplanationen wurden 
durchgeführt, um zu sehen, ob der Einfluss von Clec16a KD T-Zell intrinsisch ist. Außerdem 
wurden intraperitoneale Glukosetoleranztests durchgeführt, um den Blutzuckerstoffwechsel 
in Clec16a KD Mäusen zu beurteilen. Schließlich wurden mittels qPCR Expressionslevel der 
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benachbarten Gene, wie zum Beispiel Dexi und Socs1, erhoben, um die Eigenschaften von 
CLEC16A als quantitativer Trait Locus einzuordnen.  
 
Gemeinsam mit den Ergebnissen von Schuster et al. kann diese Arbeit aufzeigen, dass Clec16a 
KD die Ausprägung von Insulitis im Pankreas reduziert und Clec16a KD NOD Mäuse vor 
spontanem Autoimmundiabetes schützt. Dieser Schutz vor Erkrankung wird durch 
beeinträchtigte Autophagie in Thymus-Epithelzellen hervorgerufen, welche die T-Zell 
Selektion beeinflusst und die Reaktivität von T-Zellen reduziert. Der Einfluss des Clec16a KD 
ist innerhalb des Thymus wirksam. Der Blutzuckerstoffwechsel in Clec16a KD NOD Mäusen 
bleibt unverändert und kann deshalb als Ursache für den Schutz vor Type 1 Diabetes 
ausgeschlossen werden. Clec16a und Dexi zeigen ähnliche Expressionslevel auf, dennoch 
benötigt es weitere detaillierte Studien, um eine Beziehung zwischen den beiden Genen 
etablieren zu können. Letztlich konnte die Beeinträchtigung von Autophagie in menschlichen 
CLEC16A KD Zellen nachgewiesen werden, was bedeutet, dass die Funktion von CLEC16A 
evolutionär konserviert ist und ein möglicher Zusammenhang zwischen CLEC16A 
Polymorphismen und einem erhöhten Risiko für Typ 1 Diabetes im Menschen besteht.  
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